Clinical Literature for the Ohio Medicaid Preferred Drug List

References listed are those that have been reviewed to date for each class of medications. Manufacturers seeking to supply additional clinical information should not provide duplicates of the references listed. Please submit all clinical information electronically to **ohio.pdl@xerox.com.** Please note that therapeutic classes without accompanying references are currently under development.

Table of Contents

Analgesic Agents…….3
Gastroprotective NSAIDs……..3
Gout Agents……....4
Opioids……5
Topical NSAIDs……7
Blood Formation, Coagulation, and Thrombosis Agents……7
Hematopoietic Agents……7
Heparin-Related Preparations……..8
Oral Anticoagulants and Platelet Aggregation Inhibitors……..9
Cardiovascular Agents……..12
ACE Inhibitors……12
Alpha-Beta Adrenergic Blockers……17
Angiotensin Receptor Antagonists……17
Antianginal Agents……21
Antiarrhythmic Agents……..22
Beta-Blockers……23
Calcium Channel Blockers……..24
Direct Renin Inhibitors……..27
Lipotropics……..28
Lipotropic/Hypertension Combination……34
Pulmonary Arterial Hypertension Agents……..34
Central Nervous System……35
Alzheimer's Agents……35
Anticonvulsants……..37
Anti-migraine Agents – Serotonin 5-HT1 Receptor Agonists……40
Antidepressants……41
Antipsychotics, Second Generation, Oral……..44
Antipsychotics, Second Generation/SSRI Combination……47
Attention Deficit Hyperactivity Disorder Agents……47
Fibromyalgia Agents……49
Medication Assisted Treatment Agents……50
Multiple Sclerosis Agents……50
Neuropathic Pain Agents……52
Parkinson's Agents……53

Restless Legs Syndrome Agents……54
Sedative Hypnotics, Non-Barbiturate……55
Skeletal Muscle Relaxants, Non-Benzodiazepine……56
Smoking Deterrents……..57
Endocrine Agents……59
Diabetes – Amylin Analogs, Incretin Mimetics, and Insulins…….59
Oral Hypoglycemics……...61
Estrogenic Agents……..64
Growth Hormones……..67
Osteoporosis – Bone Ossification Enhancers……68
Gastrointestinal Agents……...70
Anti-Emetic Agents……70
Chronic Constipation Agents…….....71
Pancreatic Enzymes……..72
Proton Pump Inhibitors……..72
Ulcerative Colitis Agents……..……74
Genitourinary Agents……...76
Benign Prostatic Hyperplasia Agents……..76
Electrolyte Depleters……..78
Urinary Antispasmodics……78
Immunomodulators……..81
Immunomodulators for Systemic Inflammatory Disease……..81
Oral Immunosuppressants…….....82
Infectious Disease Agents……..82
Cephalosporins – Oral……82
Macrolides – Oral……...83
Quinolones – Oral……...84
Antibiotics – Inhaled……85
Antifungals for Onychomycosis & Systemic Infections……85
Antivirals – Hepatitis C……86
Antivirals – Herpes……..87
Antivirals – HIV……...88
Ophthalmic Agents……97
Antibiotics……..97
Antihistamine/Mast Cell Stabilizers……98
Miotics……..100
NSAIDs……102
Otic Agents……..103
Antibiotics……103
Respiratory Agents…….....104
Antihistamines – Second Generation……104
Beta-adrenergic Agents – Inhaled……..105
Beta-adrenergic Combinations……...108
COPD Agents……109
Glucocorticoid Agents – Inhaled……..110
Hereditary Angioedema Agents……..112

Leukotriene Receptor Modifiers and Inhibitors……112
Nasal Preparations…….....114
Self-Injectable Epinephrines……116
Topical Agents……117
Acne Agents……...117
Androgenic Agents……118
Antifungals……..119
Corticosteroids……121
Immunomodulators……...122
Parasitics……122

Analgesic Agents

Gastroprotective NSAIDs

1. Arthrotec [package insert]. New York, NY: Pfizer Inc.; September 2014.
2. Celebrex [package insert]. New York, NY: Pfizer Inc.; February 2011.
3. Duexis [package insert]. Northbrook, IL: Horizon Pharma USA Inc.; April 2011.
4. Vimovo™ [package insert]. Wilmington, DE: AstraZeneca LP; December 2014.
5. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
6. Electronic Orange Book. [cited 2013 April] www.fda.gov/cder/ob/default.htm.
7. Agrawal NM, Caldwell J, Kivitz AJ, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. *Clin Ther.* 1999 Apr;21(4):659-74.
8. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. *J Rheumatol.* 1998 Aug;25(8):1602-11.
9. Cardiovascular safety of COX-2 inhibitors. *Med Lett Drugs Ther* 2001;1118:99-100.
10. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclo-oxygenase-2. *N Eng J Med* 2001;345(6):443-42.
11. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. *JAMA* 2002;287(1):64-71.
12. Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the Efficacy of Cyclooxygenase 2-Specific Inhibitors in Treating Osteoarthritis. Appropriate Trial Design Considerations and Results of a Randomized, Placebo-Controlled Trial. *Arth Rheum* 2003; 48(11): 3102-3111.
13. Malmstrom K, et al. Comparison of rofecoxib and celecoxib in postoperative dental pain: a randomized, placebo and active

comparator controlled clinical trial *Clin Ther* Oct 1999;21(10): 1653-1663.
14. McKenna F, et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo controlled randomized, double blind study. *J Clin Rheumatol* 2001;7:151-159.
15. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. *J Am Med Assoc* 2001;286(8):954-959.
16. Scheiman JM, Yeomans ND, Talley NJ, Vakel N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. *Am J Gastroenterol* 2006 Apr; 101(4):701-10.
17. Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. *J Am Med Assoc* 2000;284(10):1247-1255.
18. Whelton A, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. *Am J Ther* 2001;8:85-95.

Gout Agents

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Colcrys [package insert]. Philadelphia, PA: AR Scientific, Inc.; August 2014.
3. Electronic Orange Book. [cited 2013 April] http://www.fda.gov/cder/ob/default.htm.
4. Probenecid [package insert]. Philadelphia, PA: Lannett Company, Inc.; July 2010.
5. Probenecid and Colchicine [package insert]. Corona, CA: Watson Pharma Inc.; June 2009.
6. Uloric [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; November 2012.
7. Zyloprim [package insert]. San Diego, CA: Prometheus Laboratories Inc.; October 2003.
8. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. Epub 2010 Apr 6.
9. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 Dec;31(12):2429-32.
10. Management of Gout. *Pharmacist's Letter* November 2010; Vol: 26.
11. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled

study of probenecid-treated patients. Arthritis Rheum. 1974 Sep-Oct;17(5):609-14.
12. Stocker SL, Graham GG, McLachlan AJ, Williams KM, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011;Feb 1.

Opioids

1. Abstral [package insert]. Portland, OR: Galena Biopharma, Inc; July 2014.
2. Actiq [package insert]. Salt Lake City, UT: Cephalon, Inc.; June 2012.
3. Butrans [package insert]. Stamford, CT: Purdue Pharma; June 2014.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Darvocet-N [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc.; September 2009.
6. Drug Facts and Comparisons 2013. Narcotic Analgesics. [cited 2013 April] http://www.efactsweb.com.
7. Electronic Orange Book. [cited 2013 April] http://www.fda.gov/cder/ob/default.htm.
8. Embeda [package insert]. NY, NY: Pfizer, Inc; October 2014.
9. Exalgo [package insert]. Hazelwood, MO: Mallinckrodt Inc.; June 2014.
10. FDA [cited 2015 March] http://www.fda.gov/cder/.
11. Fentora [package insert]. Salt Lake City, UT: Cephalon, Inc.; February 2013.
12. Hysingla [package insert]. Stamford, CT: Purdue Pharma; November 2014.
13. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. Hudson, Ohio: Lexi-Comp, Inc; 2001.
14. Nucynta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2013.
15. Nucynta ER [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2014.
16. Opana [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; July 2012.
17. Opana ER [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; January 2015.
18. Onsolis [package insert]. Somerset, NJ: Meda Pharmaceuticals, Inc.; June 2012.
19. Oxycontin [package insert]. Stamford. CT: Purdue Pharma; April 2014.
20. Roxicodone [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc.; March 2009.
21. RxList [cited 2013 April] http://www.rxlist.com.

22. Rybix [package insert]. San Diego, CA: Victory Pharma, Inc.: August 2010.
23. Ryzolt [package insert]. Stamford. CT: Purdue Pharma; December 2008.
24. Xartemis XR [package insert]. Hazelwood, MO: Mallinckrodt Inc; March 2014.
25. Zamicet [package insert]. Greenville, SC: Pharmaceutical Associates, Inc.; August 2008.
26. Zohydro ER [package insert]. San Diego, CA: Zogenix, Inc; January 2015.
27. Bruera E, Belzile M, Pituskin E et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. *Journal of Clinical Oncology* 1998; 16: 3222-3229.
28. Caldwell JR, Rapoport RJ, Davis JC et al. Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to Severe Osteoarthritis Pain: Results from a Randomized, Placebo-Controlled, Double-Blind Trial and an Open-Label Extension Trial. *Journal of Pain and Symptom Management* 2002; 23(4): 278-291.
29. De Conno F, Ripamonti C, Sbanotto A et al. A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. *Journal of Pain and Symptom Management* 1991; 6: 423-427.
30. Farrar J, Cleary J, Rauck R et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. *Journal of the National Cancer Institute*. 1998; 90: 611-616.
31. Fricke J, Karim R, Jordan D et al. A double blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. *Clinical Therapeutics* 2002; 24: 953-968.
32. Gammaitoni AR, Galer BS, Bulloch S et al. Randomized, Double-Blind, Placebo-Controlled Comparison of the Analgesic Efficacy of Oxycodone 10mg/Acetaminophen 325mg versus Controlled-Release Oxycodone 20mg in Postsurgical Pain. Journal of Clinical Pharmacology 2003; 43: 296-304.
33. Mercadante S, Casuccio A, Agnello A et al. Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home. *Journal of Clinical Oncology* 1998; 16:3656-3661.
34. Parris W, Johnson B, Croghan M et al. The use of controlled release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. *Journal of Pain and Symptom Management* 1998; 16: 205-211.

35. Portenoy RK, Sciberras A, Eliot L et al. Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine Formulation in Patients with Chronic Moderate-to-Severe Pain. *Journal of Pain and Symptom Management* 2002; 23(4): 292-300.
36. Roth S, Fleischmann R, Burch et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. *Archives of Internal Medicine* 2000; 160: 853-860.
37. Sniezek PJ, Brodland DG, Zitelli JA. A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction. *Dermatol Surg*. 2011 Jul;37(7):1007-13.
38. Turturro M, Paris P, Yealy D et al. Hydrocodone versus codeine in acute musculoskeletal pain. *Annals of Emergency Medicine* 1991; 20: 1100-1103.
39. Turturro M, Paris P, & Larkin G. Tramadol versus hydrocodone-acetaminophen in acute musculoskeletal pain: a randomized, double-blind clinical trial. *Annals of Emergency Medicine* 1998; 32: 139-143.
40. Ytterberg S, Mahowald M & Woods S. Codeine and oxycodone use in patients with chronic rheumatic disease pain. *Arthritis & Rheumatism* 1998; 41: 1603-1612.

Topical NSAIDs – Class Under Review

Blood Formation, Coagulation, and Thrombosis Agents

Hematopoietic Agents

1. Aranesp [package insert]. Thousand Oak, CA: Amgen, Inc; 2013.
2. Clinical Pharmacology [Accessed March 2015]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Epogen [package insert]. Thousand Oak, CA: Amgen, Inc; 2013.
4. Procrit [package insert]. Thousand Oak, CA: Amgen, Inc; 2013.
5. Besarb A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med* 1998; 339:584-90.
6. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. *Ann Intern Med* 2000;133:845-854.
7. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving

nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2001;19(11):2864-2874.
8. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. *Am J Kidney Dis* 2001 Jan; 37(1 Suppl 1):S182-238.
9. Nissenson AR, Swan SK, Lindberg JS, et al. randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. *Am J Kidney Dis* 2002; 40(1): 110-118.
10. Seidenfeld J, Piper M, Flamm C, Hasselbland V. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. *J Natl Cancer Inst* 2001;93:1204-14.
11. Silverberg DS, Blum M, Agbaria Z, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. *Clin Nephro* 2001; 55(3): 212-219.
12. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 2006; 355(20): 2085-98.
13. Vansteenkiste J, Pirker R, Massuti B. et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. *J Natl Cancer Inst* 2002; 94:1211-1220.

Heparin-Related Preparations

1. Arixtra [package insert]. Canonsburg, PA: Mylan Pharma, Inc; 2014.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Fragmin [package insert]. New York, NY: Pfizer, Inc; 2015.
4. Lovenox [package insert]. Bridgewater, NJ: Sanofi-Aventis LLC; 2013.
5. Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. *N Engl J Med* 2013 Aug 29;369(9):799-808.
6. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. *NEJM* 2001;345(18):1305-10.
7. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med* 2013 Feb 7;368(6):513-23.
8. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. *J Bone Joint Surg* 2001;83-a(3):336-45.
9. Drug Facts and Comparisons. Facts and Comparisons. St. Louis (MO): 2002.
10. Gordon H. Guyatt, Elie A. Akl, Mark Crowther, David D. Gutterman, Holger J. Schuünemann, and for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive Summary: Antithrombotic Therapy and Prevention of

Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012;141(2):7S-47S.
11. Hull RD, Pineo FG, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs. in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. *Arch Intern Med* 2000;160(14):2208-15.
12. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. *Lancet* 2002;359(9319):1715-20.
13. Meyer G, Marjonovic Z, Judith V, et al. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. *Arch Intern Med* 2002;162:1729-1735.
14. Michot M, Conen D, Holtz D, et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomized trial of prophylaxis with low-molecular weight heparin. *Arthroscopy* 2002;18(3):257-63.
15. Planes A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement – comparison between two low-molecular heparins, tinzaparin and enoxaparin. *Thromb Haemost* 1999;81(1):22-5.
16. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. *Lancet* 2002;359(9319):1721-6.
17. Turpie AG, Hull RD, Schellong SM, et al. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study. *Stroke*. 2013 Jan;44(1):249-51.
18. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. *Arch Intern Med* 2005;165(7):733-8.

Oral Anticoagulants and Platelet Aggregation Inhibitors

1. Brilinta [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2013.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology.com/.
3. Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
4. Effient (prasugrel) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2013.
5. Eliquis [package insert]. Princeton, NJ: BMS; 2014.
6. Orange Book. [Accessed 2013 April] Available from: URL: http://www.fda.gov/cder/ob/.

7. Pharmacist Letter [accessed 2015 March]. Available from: URL: www.rxletter.com.
8. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb Sanofi Pharmaceuticals; 2013.
9. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
10. Savaysa [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2015.
11. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2015.
12. Zontivity [package insert]. Whitehouse Station, NJ: Merck; 2014.
13. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. *NEJM* 2013; 368(8):699-708.
14. Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013 Aug 29;369(9):799-808.
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *British Medical Journal*. 324(7329):71-86, 2002 Jan 12.
16. Bertrand ME. Rupprecht HJ. Urban P. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation*. 102(6): 624-9, 2000 Aug 8.
17. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 354(16): 1706-17, 2006 April 20.
18. Bonaca MP, Scirica BM, Creager MA, et al. Voraxapar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. *Circulation* 2013 April 9; 127(14): 1522-9.
19. Braunward, et al., Management of patients with unstable angina and non-ST-segment elevation myocardial infarction update. http://www.acc.org.
20. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. *Lancet*. 375(9711): 283-93, 2010 Jan 23.
21. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet*. 348(9038):1329-39, 1996 Nov 16.
22. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. *Lancet*. 366(9497): 1607-21, 2005 Nov 5.
23. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med 2009*; 361(12): 1139-51.

24. Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke. *Lancet Neurology 2010;* 9(12): 1157-63.
25. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasy. *NEJM*. 2008; 358(26): 2765-75.
26. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. *Lancet*. 2008; 372(9632): 31-9.
27. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *NEJM*. 2008; 358(26): 2776-86.
28. Lau WC, Waskell LA< Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. *Circulation*. 107(1):32-7, 2003 Jan 7.
29. Leonardi S, Tricoci P, White HD, et al. Effect of voraxapar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. *European Heart Journal* 2013 June; 34(23): 1723-31.
30. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. *Lancet* 2012; 17; 380(9855): 1749-58.
31. Mehta SR. Yusuf S. Peters RJ. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet*. 358(9281): 527-33, 2001 Aug 18.
32. Mueller C, Roskamm H, Neumann FJ, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. *Journal of the American College of Cardiology*. 46(6):969-73, 2003 Mar 14.
33. Muller C. Buttner HJ. Petersen J. et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. *Circulation*. 101(6):590-3, 2000 Feb 15.
34. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *NEJM* 2011; 365(10): 883-91.
35. Taniuchi M. Kurz HI. Lasala JM. Randomized comparison *of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.* Circulation. 104(5):539-43, 2001 Jul 31.
36. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. *Lancet*. 2009; 373(9676): 1673-80.

37. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 361(11): 1045-57, 2009 Sept 10.
38. Wang Y, Zhao X, Liu L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med* 2013 July 4;369(1):11-9.
39. Wiviott SD, Antman EM, Winters KJ, et al for the JUMBO–TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial. *Circulation*. 2005;111:3366-3373.
40. Wiviott SD,Braunwald E, McCabe CH, et al for the TRITON–TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001-15.
41. Wiviott SD, Trenk D, Frelinger AL, et al for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation–Thrombolysis in Myocardial Infarction 44 Trial. *Circulation*. 2007;116:2923-2932.
42. Yusuf S. Zhao F. Mehta SR. et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *New England Journal of Medicine*. 345(7): 494-502, 2001 Aug 16.

Cardiovascular Agents

ACE Inhibitors

1. Accupril [package insert]. NY, NY: Pfizer, Inc. 2014.
2. Accuretic [package insert]. NY, NY: Pfizer Inc; 2014.
3. Aceon [package insert]. Cincinnati, OH: Patheon Pharma, Inc.; 2013.
4. Altace [package insert]. NY, NY: Pfizer, Inc.; 2013.
5. Capoten [package insert]. Spring Valley, NY: Par Pharma, Inc.; 2014.
6. Capozide [package insert]. Spring Valley, NY: Par Pharma, Inc.; 2008.
7. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
8. Epaned [package insert]. Greenwood Village, CO: Silvergate Pharma, Inc.; 2014.
9. Lotensin [package insert]. Parsippany, NJ: Validus Pharma; 2015.
10. Lotensin HCT [package insert]. Parsippany, NJ: Validus Pharma; 2014.
11. Lotrel [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
12. Mavik [package insert]. Whippany, NJ: Abbvie Inc.; 2014.
13. Monopril [package insert]. Princeton, NJ: BMS; 2008.
14. Monopril HCT [package insert]. Princeton, NJ: BMS; 2000.

15. Prinivil [package insert]. Whitehouse Station, NJ: Merck & Co, Inc. 2013.
16. Tarka [package insert]. North Chicago, IL: Abbvie Inc.; 2014.
17. Uniretic [package insert]. Smyrna, GA: UCB, Inc.; 2012.
18. Univasc [package insert]. Smyrna, GA: UCB, Inc.; 2012.
19. Vaseretic [package insert]. Bridgewater, NJ: Valeant Pharma; 2014.
20. Vasotec [package insert]. Bridgewater, NJ: Valeant Pharma; 2014.
21. Zestoretic [package insert]. Wilmington, DE: AZ Pharma; 2014.
22. Zestril [package insert]. Wilmington, DE: AZ Pharma; 2014.
23. Acanfora D, et al. Quinapril in patients with congestive heart failure: controlled trial versus captopril. *Am J Ther* 1997; May-Jun 4 (5/6):181-8.
24. The AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure*. Lancet* 1993;342:822-827.
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-97.
26. Angiotensin converting enzyme inhibitors. In: Hebel SK, ed. Drug Facts and Comparisons, St. Louis: Facts & Comparisons, Inc., 2001.
27. Bach R, Zardini P. Long-acting angiotensin-Converting enzyme inhibition: Once-daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure. *Am J Cardiol* 1992;70:70C-77C.
28. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. *Lancet* 2010 Apr 3;375(9721):1173-81.
29. Bounhoure JP, Boattlneau G, Lechat P, et al. Value of perindopril in the treatment of chronic congestive heart failure*. Clin & Exper- Theory & Pract* 1989;A11(Suppl 2):575-586.
30. Brown EJ, Chew PH, et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with congestive heart failure not taking digitalis*. Am J Cardiol* 1995;75:596-600.
31. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *JAMA* 2003;289:2560-77.
32. Chrysant S, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. *Arch Fam Med* 1996 Jan; 5: 17-24.
33. Chrysant S. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. *Arch Intern Med* 1994 Apr; 154: 737-43.

34. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HeFT II). *New Eng J Med* 1991;325(5):303-310.
35. Colfer HT, Ribner HS, Gradman A, et al. Effects on once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. *Am J Cardio* 1992;70:354-358.
36. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. *New Eng J Med* 1987;316:1429-1435.
37. DeQuattro V, Lee D. Efficacy of Combination Therapy with Trandolapril and Verapamil SR in Primary Hypertension: A 4 x 4 Trial Design. *Clinical and Experimental Hypertension* 1997;19(3):373-387.
38. Elliott WJ, Montoro R, Smith D, Leibowitz M, Hwang C, Gradman AH. Comparison of Two Strategies for Intensifying Antihypertensive Treatment: Low-Dose Combination (Enalapril + Felodipine ER) Versus Increased Dose of Monotherapy (Enalapril). *American Journal of Hypertension* 1999;12:691-696.
39. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). *Lancet* 2003;362:782-788.
40. FEST Study Group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. *Eur Heart J* 1995:16:1892-1899.
41. Fogari R, Corea L, Cardoni O, Cosmi F, Porcellati C, Innocenti P. Combined Therapy with Benazepril and Amlodipine in the Treatment of Hypertension Inadequately Controlled by an ACE Inhibitor Alone. *Journal of Cardiovascular Pharmacology* 1997;30:497-503.
42. Frishman WH, Ram VS, McMahon FG, Chrysant SG, Graff A, Kupiec JW. Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. *Journal of Clinical Pharmacology* 1995; 35:1060-1066.
43. Gavazzi A, Marioni R. Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure. *J Hypertens* 1994;12(S4):S89-S93.
44. The GISSI-3 APPI Study Group. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: The GISSI-3 trial. J *Am Coll Cardiol* 1996;27(2):337-344.
45. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Long-Term Efficacy, Tolerability, and Safety of the Combination of Enalapril and Felodipine ER in the Treatment of Hypertension. *Clinical Therapeutics* 1998;20(3):527-538.
46. Guthrie R, Reggi D, Plesher M, Saini R, Battikha J. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. *Am J Hypertens* 1996; 9: 306-11.

47. Heart Failure: Management of patients with left ventricular systolic dysfunction. Clinical Practice Guideline, No. 11. Rockville, MD. U.S. Department of Health and Human services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 94-0613.
48. Holwerda K, Hoogma R, Oldenbroek C, Huige R, Wester A, Rijnierse J Efficacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy. *Clinical Therapeutics* 1994; 16(6): 942-51.
49. Kaplan, N. Hypertension essentials. Royal Oak, Michigan: Physicians' Press; 2000.
50. Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. *Blood Pressure* 2000; 9(2-3): 140-5.
51. Kober L, Torp-Pedersen C, Carlsen J et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction (TRACE*). N Eng J Med* 1995;333:1670-1676.
52. Kuschnir E, Acuna E, Sevilla D, Vasquez J, Bendersky M, Resk J. Treatment of Patients with Essential Hypertension: Amlodipine 5 mg/Benazepril 20 mg Compared with Amlodipine 5 mg, Benazepril 20 mg, and Placebo. *Clinical Therapeutics* 1996;18(6)1213-1224.
53. Lacy C, et al. Drug Information Handbook, 9th ed. Hudson, Ohio:Lexi-Comp Inc., 2005.
54. Lechat P, Garnham SP, Desche P, et al. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. *Am Heart J* 1993;126(3):798-806.
55. Lenz T, Schulte L, Wagner B, Lilienthal J, Gotzen R. Quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. *Eur Heart J* 1994; 15: 940-6.
56. Malacco E, Piazza S, Caretta R, Di Somma S, Mugellini A, Bertocchi F, et al. Comparison of benazepril-amlodipine and the captopril-thiazide combinations in the management of mild to moderate hypertension. *Inter J Clin Pharm Ther* 2002; 40: 263-269.
57. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition on Progressive Renal Insufficiency Study Group. *New Eng J Med* 1996;334(15):939-945.
58. Messerli F, Frishman WH, Elliott WJ. Effects of Verapamil and Trandolapril in the Treatment of Hypertension. *American Journal of Hypertension* 1998:11:322-332.
59. Morisco C, et al. Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril. *Cardiovasc Drugs Ther.* Mar 1997;11(1): 63-69.

60. Os I, Hotnes T, Dollerup J, Mogensen C. Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. *Am J Hypertens* 1997; 10: 899-904.
61. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease. The International Verapamil-Trandolopril Study (INVEST): A Randomized Controlled Trial. *JAMA* 2003; Dec 3; 290 (21): 2805-16.
62. Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. *Eur J Clin Pharmacol* 1996;50:259-64.
63. Pflugfelder PW, Baird MG, Tonkon MJ, et al. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: A double blind, placebo-controlled study of quinapril. *J Am Col Cardiol* 1993;22(6):1557-63.
64. Pool J, Kailhlanen P, Lewis G, Ginsberg D, Oparil S, Glazer Messerli FH. Once-daily Treatment of patients with Hypertension: A Placebo-Controlled Study of Amlodipine and Benazepril vs Amlodipine or Benazepril Alone. *Journal of Human Hypertension* 2001;15:495-498.
65. Ruddy MC, Mroczek WJ. Comparison of ramipril and enalapril in patients with essential hypertension. *Pharmacotherapy* 1993 May-Jun;13(3):224-8.
66. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *New Eng J Med* 1991;325:293-302.
67. Squire LB, Violet I, Chiche M, Lembours G. Acceptability of long-term perindopril in the treatment of mild to moderate chronic congestive heart failure. *Clin Cardiol* 1996;19(Supp I):I-9 – I-15.
68. Stimple M, Koch B, Dickstein K. Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. *Cardiology* 1996; 87:313-8.
69. Stimpel M, Koch B, Jansen T, Fox A, Loh I. Moexipril versus captopril in patients with mild to moderate hypertension. *J Cardiovasc Pharmacol* 1996;28(6):769-73.
70. Tatti P, et al. Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients with Hypertension and NIDDM. *Diabetes Care* 1998:21:597-603.
71. VeraTran Study Group. Effects of Verapamil SR, Trandolapril, and Their Fixed Combination on 24-h Blood Pressure. *American Journal of Hypertension* 1997:10:492-499.
72. White WB, Stimple M. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. *J Human Hypertens* 1995 Nov; 9(11): 879-84.

73. Yasky J, et al. Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. *Br J Clin Pract* 1996;50(6):302-310.
74. Yajnik VH, et al. Ramipril vs captopril in mild to moderate hypertension. *J Assoc Physicians India* 1994 Feb;42(2)120-3.
75. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Eng J Med* 2000;342:145-153.

Alpha-Beta Adrenergic Blockers

1. Coreg [package insert]. Research Triangle Park, NC: GSK; 2011.
2. Coreg CR [package insert]. Research Triangle Park, NC: GSK; 2011.
3. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
4. Bakrin GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; 292(18): 2227-36.
5. Metra M, Giubbini R, Nodari S et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. *Circulation.* 2000;102(5):546-51.
6. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J of Med*. 2001;344(22):1651-8.
7. Poole-Wilson P, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. *Lancet* 2003;362:7-13.
8. Van der Does R, Hauf-Zachariou U, Pfarr E et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. *Am J of Cardiol.* 1999;83(5):643-9.

Angiotensin Receptor Antagonists

1. Atacand [package insert]. Wilmington, DE: AZ; 2015.
2. Atacand HCT [package insert]. Wilmington, DE: AZ; 2015.
3. Avalide [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2014.
4. Avapro [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2014.
5. Azor [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2014.
6. Benicar [package insert]. Parsippanny, NJ: Daiichi Sankyo, Inc; 2014.
7. Benicar HCT [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2014.
8. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
9. Cozaar [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2014.
10. Diovan [package insert]. East Hanover, NJ: Novartis Pharma; 2014.

11. Diovan HCT [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
12. Edarbi [package insert]. Deerfield, IL: Takeda Pharma; 2014.
13. Edarbyclor [package insert]. Deerfield, IL: Takeda Pharma; 2014.
14. Exforge [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
15. Exforge HCT [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
16. Hyzaar [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2014.
17. Micardis [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharma, Inc.; 2014.
18. Micardis HCT [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharma, Inc; 2014.
19. Teveten [package insert]. North Chicago, IL: Abbvie, Inc.; 2014.
20. Teveten HCT [package insert]. North Chicago, IL: Abbvie, Inc.; 2014.
21. Tribenzor [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2014.
22. Twynsta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharma, Inc; 2014.
23. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson E, Wang, E. Antihypertensive efficacy of Candsartan in comparison to Losartan: The CLAIM study. *Journal of Clinical Hypertension.* 2001; January/February (3): 16-21.
24. Ball K. A multi-center, double blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension. *Journal of Hypertension* 2001; 19 (suppl 2): S153.
25. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med* 2004; 351(19): 1952-61.
26. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. *J of Human Hypertension* 1998;12:861-6.
27. Brenner BM, Cooper ME, DeZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-9.
28. Campbell M, Sonkodi S, Soucek M, Wiecek A. A Candesartan Cilexetil/Hydrochlorothiazide Combination Tablet Provides Effective Blood Pressure Control in Hypertensive Patients Inadequately Controlled on Monotherapy. *Clin and Exper Hypertension* 2001;23(4):345-355.
29. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *JAMA* 2003;289:2560-77.

30. Chrysant S, Weber M, Wang A, Hinman D. A Factorial Design to Assess the Safety and Efficacy of Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy. *The Eighteenth Annual Scientific Meeting of the American Society of Hypertension*. New York, New York: May 14-17 2003.
31. Cohn JN, Tognoni G et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345:1667-75.
32. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus Valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double blind, 12 weeks trial. *Clinical Therapeutic* 2001; Aug 23(8):1166-79.
33. Flack JM, Saunders E, Gradman A, Kraus WE, Lester Fm, Pratt JH. Antihypertensive Efficacy and Safety of Losartan Alone and in Combination with Hydrochlorothiazide in Adult African Americans with Mild to Moderate Hypertension. *Clin Therapeutics* 2001;23(8):1193-1208.
34. Gradman A, Lewin A, Bowlin B, Tonkon M, Deedwania P, Kezer A, Hardison D, Cushing D, Michelson E. Comparative effects of Candesartan cilexetil and Losartan in patients with systemic hypertension. *Heart Disease* 1999; 1:52-57.
35. Gradman AH, Gray J, Maggiacomo F, Punzi H, White W. Assessment of once daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. *Clinical Therapeutics* 1999; March 21(3) 442-453.
36. Grosso, A., Jin J., Chen J. An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension. Full Clinical Study Report 2008. Novartis Clinical Trial Results Database (accessed May 2009) http://www.novartisclinicaltrials.com.
37. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J, Oddou-Stock P. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. *American Journal of Hypertension* 1999; 12(4): 414-417.
38. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, Irbesartan and Losartan, in mild to moderate hypertension. *American Journal of hypertension* 1998; 11: 445-453.
39. Lacourciere Y, Gil-Extremera B, Mueller O et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. *Int J Clin Pract* 2003; 57(4): 273-79.

40. Lacourciere T, Tytus R, O'Keefe D, Lenis J, Orchard R, Martin K. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. *J of Human Hypertension* 2001;15:763-70.
41. Levine B. Eprosartan Provides Safe and Effective Long-Term Maintenance of Blood Pressure Control in Patients with Mild to Moderate Essential Hypertension. *Curr Med Res Opin* 2001;17(1):8-17.
42. Mallion JM, Siche JP, Lacourcier Y. ABPM comparison of the antihypertensive profile of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension. *Journal of Human Hypertension* 1999; 13: 657-664.
43. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of Losartan and Candesartan Monotherapy in Patients with Mild to Moderate Hypertension. *Clin Therapeutics* 2000; 22(10):1186-1203.
44. McGill JB and Reilly PA. Telmisartan Plus Hydrochlorothiazide Versus Telmisartan or Hydrochlorothiazide Monotherapy in Patients with Mild to Moderate Hypertension: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial. *Clin Therapeutics* 2001;23(6):833-850.
45. Ohman KP, Milon H, Valnes K. Efficacy and Tolerability of a Combination Tablet of Candesartan Cilexetil and Hydrochlorothiazide in Insufficiently Controlled Primary Hypertension-Comparison with a Combination of Losartan and Hydrochlorothiazide. *Blood Pressure* 2000;9:214-20.
46. Oparil S, Guthrie R, Lewin A, Marbury T, Reilly K, Tricari J, Witcher J. An elective titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. *Clinical Therapeutic* 1998; 398-408.
47. Oparil S, Williams D, Chrysant S, Marbury T, Neutek J. Comparative efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the control of essential hypertension. *The Journal of Clinical Hypertension* 2001; 3: September/ October 283-292.
48. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration (accessed Dec 2010) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.
49. Owens P, Kelly L, Nallen R, Ryan D, Fitzgerald D, O'Brien E. Comparison of antihypertensive and metabolic effects of Losartan and Losartan in combination with hydrochlorothiazide – a randomized controlled trial. *J of Hypertension* 2000;18(3):339-345.
50. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349:1893-906.
51. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003;362:759-66.

52. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. *Clin Ther*. 2007;29:563-580.
53. Raskin P, Guthrie R, Flack JM, Reeves RA, Saini R. The Long-term Antihypertensive Activity and Tolerability of Irbesartan with Hydrochlorothiazide. *J of Human Hypertension* 1999;13:683-687.
54. Sachse A, Verboom CN, Jager B. Efficacy of Eprosartan in Combination with HCTZ in Patients with Essential Hypertension. *J of Human Hypertension* 2002;16:169-176.
55. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. *J Clin Hypertens* (Greenwich). 2007;9:355-364.
56. White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockage in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Human Hypertens 2009 Dec;23(12):817-25.
57. White WB, Murwin D, Chrysant SG, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. *Blood Press Monit* 2008;13(1):21-7.
58. Wolters Kluwer Health, Inc. (accessed 2009 May). Facts & Comparisons 4.0, [Exforge HCT, amlodipine, valsartan, and hydrochlorothiazide monographs]. URL:http://online.factsandcomparisons.com.

Antianginal Agents

1. Clinical Pharmacology [Accessed 2015 March]. Available from: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. CV Therapeutics for Gilead Sciences, Inc: Ranexa Prescribing Information PDF. Available at: http://www.ranexa.com. Accessed March 26, 2013.
3. Ranexa [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2013.
4. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309-16.
5. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566-75.

6. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375-82.
7. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311-6.

Antiarrhythmic Agents

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Cordarone [package insert]. Philadelphia, PA: Pfizer Inc.; 2014.
3. Multaq [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2014.
1. Norpace [package insert]. New York, NY: Pfizer Inc.; 2006.
2. Norpace CR [package insert]. New York, NY: Pfizer Inc.; 2006.
3. Rythmol [package insert]. Research Triangle Park, NC: GSK; 2013.
4. Rythmol SR [package insert]. Research Triangle Park, NC: GSK; 2013.
5. Tambocor [package insert]. Scottsdale, AZ: Medicis; 2011.
6. Tikosyn [package insert]. New York, NY: Pfizer Inc.; 2013.
7. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N Engl J* Med. 1989 Aug 10;321(6):406-12.
8. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med*. 1991 Mar 21;324(12): 781-8.
9. Kim SG, Hallstrom A, Love JC, et al. Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs Implantable Defibrillators (AVID) trial and nonrandomized registry patients. *Am J Cardiol*. 1997 Aug 15;80(4):454-7.
10. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. Epub 2010 Apr 6.
11. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol. 1996 Jan 25;77(3):53A-59A.
12. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden

cardiac death in heart failure trial. Circulation. 2009 Dec 1;120(22):2170-6. Epub 2009 Nov 16.
13. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993 Mar 1;71(7):558-63.
14. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med.* 2002 Dec 5;347(23):1825-33.

Beta-Blockers

1. Betapace [package insert]. Wayne, NJ: Bayer Healthcare Pharma; 2011.
2. Betapace AF [package insert]. Wayne, NJ: Bayer Healthcare Pharma; 2011.
3. Bystolic [package insert]. St. Louis, MO: Forest Pharma, Inc.; 2011.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Corgard [package insert]. NY, NY: Pfizer, Inc.; 2013.
6. Corzide [package insert]. NY, NY: Pfizer, Inc.; 2013.
7. Inderal [package insert]. Philadelphia, PA: Wyeth Pharma, Inc; 2011.
8. Inderal LA [package insert]. Philadelphia, PA: Wyeth Pharma, Inc; 2011.
9. Inderide [package insert]. Philadelphia, PA: Wyeth Pharma, Inc; 2011.
10. InnoPran XL [package insert]. Cranford, NJ: Akrimax Pharma, Inc; 2013.
11. Kerlone [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2011.
12. Lopressor [package insert]. Parsippany, NJ: Validus Pharma; 2013.
13. Sectral [package insert]. Bridgewater, NJ: Promius Pharma; 2011.
14. Sotylize [package insert]. Atlanta, GA: Arbor Pharma; 2014.
15. Tenormin [package insert]. Wilmington, DE: AZ Pharma; 2012.
16. Toprol XL [package insert]. Wilmington, DE: AZ Pharma; 2014.
17. Trandate [package insert]. San Diego, CA: Prometheus Labs; 2010.
18. Zebeta [package insert]. Pomona, NY: Duramed Pharma; 2011.
19. Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). *Cardiovasc Drugs Ther. 2003*; 17(3): 257-263.
20. Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. *Blood Press Suppl.* 2003; 2:35-40.
21. Hjalmarson A. Goldstein, S. Fagerberg, B. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure. The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). *JAMA* 2000;283(10):1295-302.
22. Lameijer LD, Houtzagers JJ, Voermans LA. A comparative study of atenolol and penbutolol in hypertensive patients. *Eur Heart J* 1983; 4(Suppl. D):53-6.

23. Mroczek WJ, Burris JF, Hogan LB et al. Comparison of the antihypertensive effects of betaxolol to atenolol. *Am J Cardiol* 1988; 61(10):807-11.
24. Van Nueten L, Taylor FR, Robertson JIS, et al. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. *Journal of Human Hypertension* 1998; 12(2): 135-140.

Calcium Channel Blockers

1. Adalat CC [package insert]. Whitehouse Station, NJ: Merck, Inc.; 2011.
2. Cardene [package insert]. Redwood City, CA: PDL Biopharma, Inc; 2001.
3. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
4. Covera-HS [package insert]. NY, NY: Pfizer, Inc; 2011.
5. DynaCirc CR [package insert]. Liberty Corner, NJ: Reliant Pharma, Inc; 2005.
6. Nimotop [package insert]. St. Petersburg, FL: Cardinal Health; 2006.
7. Norvasc [package insert]. NY, NY: Pfizer, Inc; 2013.
8. Nymalize [package insert]. Atl, GA: Arbor Pharma; 2013.
9. Plendil [package insert]. Wilmington, DE: AZ Pharma; 2012.
10. Agodoa LY, Appel L, Bakris GL et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA*. 285(21):2719-28, 2001 Jun 6.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-97.
12. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010 Apr 3;375(9721):1173-81.
13. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) *Lancet.* 356(9227):366-72, 2000 Jul 29.
14. Calcium Channel Blockers. In: Hebel SK, ed. Drug Facts and Comparisons, St. Louis: Facts & Comparisons, Inc., 2001.
15. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *JAMA* 2003;289:2560-77.

16. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. *Circulation.* 96(3):856-63, 1997 Aug 5.
17. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. *American Journal of Cardiology*. 87(6):727-31, 2001 Mar 15.
18. Dens JA, Desmet WJ, Coussement P et al. Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. *American Journal of Cardiology*. 87(1):28-33, 2001 Jan 1.
19. Emanuelsson H, Egstrup K, Nikus K et al. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. *American Heart Journal.* 137(5):854-62, 1999 May.
20. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *New England Journal of Medicine*. 338(10):645-52, 1998 Mar 5.
21. Frishman WH, Glasser S, Stone P et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. *American Journal of Cardiology.* 83(4):507-14, 1999 Feb 15.
22. Gradman AH, Cutler NR, Davis PJ. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. *American Journal of Cardiology*. 79(4):431-5, 1997 Feb 15.
23. Hall WD, Reed JW, Flack JM et al. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. *Archives of Internal Medicine.* 158(18):2029-34, 1998 Oct 12.
24. Hansson L, Hedner T, Lund-Johansen P. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 356(9227):359-65, 2000 Jul 29.
25. Jorgensen B, Simonsen S, Endresen K et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). *Journal of the American College of Cardiology*. 35(3):592-9, 2000 Mar 1.

26. Kloner RA, Sowers JR, DiBona GF et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. *American Journal of Cardiology*. 77(9):713-22, 1996 Apr 1.
27. Lacy C, et al. Drug Information Handbook, 9th ed. Hudson, Ohio:Lexi-Comp Inc., 2005.
28. Mehta JL, Lopez LM, Vlachakis ND. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. *American Heart Journal.* 125(6):1704-10, 1993 Jun.
29. Messerli FH, Oparil S, Feng Z et al. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist(either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. *American Journal of Cardiology*. 86(11):1182-7, 2000 Dec 1.
30. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure - The CAMELOT Study: a randomized controlled trial. *JAMA*. 292(18): 2217-26, 2004 Nov 10.
31. Packer M, O'Connor CM, Ghali K et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. *New England Journal of Medicine*. 335(15):1107-14, 1996 Oct 10.
32. Pepine CJ, Cooper-DeHoff RM, Weiss RJ et al. Comparison of effects of nisoldipine-ER and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. *American Journal of Cardiology*. 91:274-79, 2003 Feb 1.
33. Poole-Wilson PA, Lubsen J, Kirwan B et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. *Lancet.* 364: 849-57, 2004 Sept 4.
34. Saunders E, Weir MR, Kong BW. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. *Archives of Internal Medicine*. 150(8):1707-13, 1990 Aug.
35. Thadani U, Zellner SR, Glasser S. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. *Circulation*. 84(6):2398-408, 1991 Dec.
36. Udelson JE, DeAbate CA, Berk M et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. *American Heart Journal*. 139(3):503-10, 2000 Mar.
37. Waters D, Lesperance J, Francetich M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. *Circulation.* 82(6):1940-53, 1990 Dec.

38. Weber MA, Goldberg AI, Faison EP et al. Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. *Clinical Pharmacology & Therapeutics.* 55(3):346-52, 1994 Mar.

Direct Renin Inhibitors

1. Amturnide [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Tekamlo™ [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
4. Tekturna [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
5. Tekturna HCT [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
6. Anderson K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month randomized, double-blind trial. *J Hypertens*. 2008 Mar;26(3):589-99.
7. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomized parallel-group trial. *Lancet*. 2011; Jan 22;377(9762):312-20.
8. Fang H, Oparil S, Patel S, Satlin A, Yarows SA, Zhang J. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. *Lancet*. 2007; 370(9583): 221-9.
9. Fang H, Oparil S, Patel S, Yarows SA, Zhang J. Aliskiren and valsartan in stage 2 hypertension: a subgroup analysis of a randomized, double-blind study. *Advances in Therapy*. 2008; 25(12): 1288-302.
10. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. *Circulation*. 2005;111:1012-18.
11. Jordan J, Engeli S, Boye SW, Breton SL, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. *Hypertension*. 2007;49:1047-1055.
12. Oh BH, Mitchell J, Herron JR, Chung J, Khan MKeefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. *J Am Coll Cardiol*. 2007;49:1157-63.
13. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an orallt effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens*. 2007;20:11-20.
14. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive

antihypertensive efficacy when used in combination with hydrochlorothiazide. *J Hypertens*. 2007;25:217-226.
15. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. *J Renin Angiotensin Aldosterone Syst*. 2007 Dec;8(4):190-8.

Lipotropics

1. Advicor [package insert]. North Chicago, IL: Abbvie; 2012.
2. Altoprev [package insert]. Ft. Lauderdale, FL: Watson Labs; 2014.
3. Antara [package insert]. Baltimore, Maryland: Lupin Pharma; 2013.
4. Clinical Pharmacology [Accessed 2015 March] http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Colestid [package insert]. New York, NY: Pfizer; 2013.
6. Crestor [package insert]. Wilmington, DE: AZ Pharma; 2014.
7. Fibricor [package insert]. Philadelphia, PA: Mutual Pharma, Inc.; 2014.
8. Lescol/Lescol XL [package insert]. East Hanover, NJ: Novartis Pharma; 2012.
9. Lipitor [package insert]. New York, NY: Pfizer; 2015.
10. Lipofen [package insert]. Juncos, Puerto Rico: Galephar Pharma, Inc.; 2013.
11. Liptruzet [package insert]. Whitehouse Station, NJ: Merck; 2014.
12. Livalo [package insert]. Montgomery, Al: Kowa Pharma, Inc.; 2013.
13. Lopid [package insert]. New York, NY: Pfizer; 2014.
14. Lovaza [package insert]. Research Triangle Park, NC: GSK; 2014.
15. Mevacor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014.
16. Niacor [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Incorporated; 2000.
17. Niaspan [package insert]. North Chicago, IL: Abbvie; 2013.
18. Pravachol [package insert]. Princeton, NJ: BMS; 2012.
19. Questran [package insert]. Spring Valley, NY: Par Pharma, Inc; 2006.
20. Simcor [package insert]. North Chicago, IL: Abbvie; 2013.
21. Tricor [package insert]. North Chicago, IL: Abbvie; 2013.
22. Trilipix [package insert]. North Chicago, IL: Abbvie; 2012.
23. Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc; 2014.
24. Vytorin [package insert]. Whitehouse Station, NJ: Merck; 2015.
25. WelChol [package insert]. Parsippany, NJ: Daiichi Sankyo; 2014.
26. Zetia [package insert]. Whitehouse Station, NJ: Merck; 2014.
27. Zocor [package insert]. Whitehouse Station, NJ: Merck; 2015.
28. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74. Epub 2010 Mar 14.
29. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin

therapy. *N Engl J Med*. 2011 Dec 15;365(24):2255-67. Epub 2011 Nov 15.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Health Attack trial (ALLHAT-LLT). *Journal of the American Medical Association* 2002;288(23):2998-3007.
31. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). *N Engl J Med*. 2006;355:549-59.
32. Balasubramanyam A, Coraza I, Smith EO, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011 Jul;96(7):2236-47. Epub 2011 May 11.
33. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. *Am J Cardiol* 2004;93(12):1487-94.
34. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). *Am J Cardiol.* 2008 May 15;101(10):1428-36.
35. Ballantyne CM, Pazzucconi F, Pinto X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. *Clinical Therapeutics* 2001; 23(2):177-192.
36. Bayes HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor versus other cholesterol-modulating agents trial evaluations [ADVOCATE]). *Am J Cardiol* 2003;91(6):667-72.
37. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. *Am J Cardiol*. 2006;98:71i-76i.
38. Cannon CP, Braumwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-1504.
39. Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. *Am J Cardiol* 2003;91(11):1304-10. (abstract)
40. Colhoun HM, Betteridge DJ, Durrington PA, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the

Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. *Lancet* 2004;364:685-96.
41. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. *American Journal of Cardiology* 1997; 79(11): 1475-1481.
42. Davidson MH, Lukacsko P, Sun JX, et al. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. *Clinical Therapeutics* 2002;24(1):112-25.
43. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. *J Am Coll Cardiol* 2002;40(12):2125-34.
44. Despres JJ, Lemieux I, Salomon H, et al. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. *J Intern Med* 2002;251(6):490-9.
45. Downs, JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atheroschlerosis Prevention Study. *Journal of the American Medical Association* 1998; 279:1615-1622.
46. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. *Heart*. 2001;85:544-8.
47. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2007 Jul;29(7):1354-67.
48. Eriksson M, Hadell K, Holme I, et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. *J Inter Med* 1998;243(5):373-80.
49. Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010 Feb 15;105(4):487-94. Epub 2009 Nov 13.
50. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult treatment Panel III low-density lipoprotein cholesterol goals. *Am J Cardiol* 2004;93(12):1481-6.
51. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus

(the FIELD study): randomized controlled trial. *Lancet* 2005:366:1849-61.
52. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. *Arch Intern Med* 2002;162(14):1568-76.
53. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. *Arch Intern Med* 2000;160(8):1177-84.
54. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. *Lancet* 2002;360(9236):7-22.
55. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atheroschlerosis Study [LCAS]). *American Journal of Cardiology* 1997; 80:278-286.
56. Insua A, Massari F, Rodriquez-Moncalvo JJ, et al. Fenofibrate or gemfibrozil for treatment of types IIa and IIb primary hyperlipidemia: a randomized, double-blind, crossover study. *Endocr Pract* 2002;8(2):96-101.
57. Insull W Jr., Davidson MH, Demke DM, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. *Atherosclerosis* 1995;112(2):223-35 (abstract only).
58. Insull W jr., Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. *May Clin Proc* 2001;76(10):971-82.
59. Iversen SA, Davidson D, Davidson C. The acceptability of resin therapy to patients attending a hospital lipid clinic. *Br J Clin Pharmacol* 1995;40(1):92-4.
60. Jacotot B, Benghozi R, Pfister P, Holmes D. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group. *American Journal of Cardiology* 1995; 76(2):54A-56A.
61. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). *American Journal of Cardiology* 1998; 81: 582-587.
62. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trail). *American Journal of Cardiology* 2003; 93:152-160.

63. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. *Am J Cardiol* 2002;89(6):672-8.
64. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. *N Engl J Med.* 2008 Apr 3;358(14):1431-43.
65. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministration with lovastatin in primary hypercholesterolemia. *Am J Cardiol* 2003;91(14):418-24.
66. Klasco RK (Ed): DRUGDEX® System (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. (cited 2008 December).
67. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. *Am J Med* 2001;110(5):352-60.
68. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. *Circulation* 2003;107(1):32-7.
69. Levin A, Duncan L, Djurdjev O, et al. A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. *Clin Nephrol* 2000;53(2):140-6.
70. Lintott CJ, Scott RS, Sutherland WH, Bremer J. Treating hypercholesterolemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. *Australian and New Zealand Journal of Medicine* 1993; 23(4): 381-386.
71. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.. *J Am Coll Cardiol* 2006 Apr 18;47(8):1584-7.
72. Nash DT. Meeting national cholesterol education goals in clinical practice - - a comparison of lovastatin and fluvastatin in primary prevention. *American Journal of Cardiology* 1996; 78(6A): 26-31.
73. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-1389.
74. Recto CS 2nd, Acosta S, Dobs A. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. *Clinical Cardiology* 2000; 23(9): 682-688.
75. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). *N Engl J Med* 2008;359:2195-207.
76. Rossebo AB, Pedersen TR, Boman K. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med.* 2008 Sep 25;359(13):1343-56. Epub 2008 Sep 2.

77. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. *N Engl J Med* 1999;341(6):410-8.
78. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *New England Journal of Medicine* 1996; 335:1001-1009.
79. Schwartz GG, Olsson AG, Ezekowitz ME, et al. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. The MIRACL Study: A Randomized Controlled Trial. *Journal of the American Medical Association* 2001;285(13):1711-1718.
80. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. *Lancet* 2003;361(9364):1149-58.
81. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. *Lancet* 2002;360(9346):1623-30.
82. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *New England Journal of Medicine* 1995; 333: 1301-1307.
83. Simons LA. Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolemia (the six cities study). *Australian and New Zealand Journal of Medicine.* 1998; 28(3): 327-333.
84. Stalenhoef AFH, Graaf J, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. *Atherosclerosis*. 2000;153:129-38.
85. Thuraisingham S, Tan KH, Chong KS, et al. A randomized comparison of simvastatin versus simvastatin and low cholesterol diet in the treatment of hypercholesterolemia. *International Journal of Clinical Practice* 2000; 54(2): 78-84.
86. Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. *J Pediatr* 1996;129(1):42-9 (abstract only).
87. U.S. Department of Health and Human Services, Food and Drug Administration, Center of Drug Evaluations and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence

Evaluations. (http://www.fda.gov/cder/ob/default.htm), accessed Dec 2012.
88. van Dam MJ, Penn HJ, den Hartog FR, et al. A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. *Clinical Therapeutics* 2001; 23(3): 467-478.
89. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM, Carter R, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. *J Am Coll Cardiol*. 2006;48:1793-9.
90. Wierzbicki AS, Lumb PJ, Chik G. Comparison of therapy with simvastatin 80 mg and atorvastatin 80mg in patients with familial hypercholesterolemia. *International Journal of Clinical Practice* 1999, 43: 609-611.
91. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol. 2010 Mar 1;105(5):656-63. Epub 2009 Dec 24.

Lipotropic/Hypertension Combination

1. Caduet [package insert]. NY, NY: Pfizer, Inc; 2014.

Pulmonary Arterial Hypertension Agents

1. Adcirca [package insert]. Indianapolis, IN: Eli Lilly and Co; 2014.
2. Adempas [package insert]. Whippany, NJ: Bayer Healthcare Pharma, Inc.; 2014.
3. Flolan [package insert]. Research Triangle Park, NC: GSK; 2011.
4. Gold Standard, Inc (accessed March 2015). Clinical Pharmacology, URL:http://clinicalpharmacology.com.
5. Letairis [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2014.
6. Opsumit [package insert]. South San Francisco, CA: Actelion Pharma, Inc.; 2013.
7. Orenitram [package insert]. Research Triangle Park, NC: United Therapeutics Corp.; 2014
8. Revatio [package insert]. NY, NY: Pfizer, Inc; 2014.
9. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corp.; 2013.
10. Tracleer [package insert]. South San Francisco, CA: Actelion Pharma; 2013.
11. Tyvaso [package insert]. Research Triangle Park, NC: United Therapeutics Corp.; 2014.
12. Veletri [package insert]. South San Francisco, CA: Actelion Pharma; 2012.

13. Ventavis [package insert]. South San Francisco, CA: Actelion Pharma; 2013.
14. Hopkins W, Rubin LJ. Treatment of Pulmonary Hypertension. Wolters Kluwer Health Clinical Solutions; UpToDate. February 2012. Available at: http://www.uptodate.com.
15. Medline Plus Health Information from the National Library of Medicine. Accessed May 2012. Available from www.medlineplus.com.
16. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration (accessed May 2012) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.

Central Nervous System Agents

Alzheimer's Agents

1. Aricept [package insert]. Woodcliff Lake, NJ: Esai, Inc; 2013.
2. Clinical Pharmacology [Accessed 2015 March]. http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Exelon [package insert]. East Hanover, NJ: Novartis Pharma; 2015.
4. Exelon Patch [package insert]. East Hanover, NJ: Novartis Pharma; 2015.
5. Namenda [package insert]. St. Louis, MO: Forest Pharma, Inc.; 2013.
6. Namenda XR [package insert]. St. Louis, MO: Forest Pharma, Inc.; 2014.
7. Razadyne [package insert]. Titusville, NJ: Janssen Pharma; 2015.
8. Birks J, Grimley EJ, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). In the Cochrane Library, Issue 1, 2003. Oxford: Update Software.
9. Birks JS, Melzer D, Beppu H. Donepezil for mild to moderate Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
10. Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders* 2005; 20(2-3): 120-32.
11. Dipiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy, A Pathophysiological Approach. New York: McGraw-Hill; 2002.
12. Drug Facts & Comparisons (on-line version). Central Nervous System Agents [cited 2004 Jan 29]. http://www.efactsweb.com.
13. Electronic Orange Book. [cited 2009 May]. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.
14. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. *N Engl J Med* 2004; 351(24): 2509-18.
15. Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. *Can Med Assoc J* 2002;166:616-23.

16. Hogan DB, Patterson C. Treatment of Alzheimer's disease and other dementias: review and comparison of the cholinesterase inhibitors. *Can J Neurol Sci* 2002;29:306-14.
17. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. *JAMA* 1994;271:985-991.
18. Knopman D. Pharmacotherapy for Alzheimer's disease: 2002. *Clinical Neuropharmacology* 2003;26(2):93-101.
19. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. *N Engl J Med* 2003;348;1356-64.
20. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
21. Orgogozo, J. Efficacy and safety of memantine in patients with mild to moderate vascular dementia – A randomized, placebo-controlled trial (MMM 300). *Stroke* 2002;33(7):1834-1839.
22. Qaseem A, Snow V, Cross T, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. *Ann Intern Med.* 2008; 148:370-378.
23. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med* 2003;348(14):1333-41.
24. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology* 1998;50:136-145.
25. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. *British Medical Journal* 1999;318:633-38.
26. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 2004;291(3):317-324.
27. Wilcock GK, Lilienfield S, Gaens E, et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomized controlled trial. *British Medical Journal* 2000:321:1445-49.
28. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomized, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. *Int J Clin Pract* 2002; 56:441-46.
29. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo controlled study of donepezil in patients with mild to moderate Alzheimer's disease. *Neurology* 2001;57:489-95.
30. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. *Lancet* 2006; 367(9516): 1057-65.

31. Winblad B and Poritis N. Memantine in severe dementia: results of the M-Best study (benefit and efficacy in severely demented patients during treatment with memantine). *Int J Geriat Psychiatry* 1999;14(2):135-46.
32. Wolfson C, Oremus M, Vijay S, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness. *Clinical Therapeutics* 2002;24:862-886.

Anticonvulsants

1. Clinical Pharmacology. [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Drugs@FDA. [Accessed 2015 March] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012 Jul;11(7):579-88. doi: 10.1016/S1474-4422(12)70105-9. Epub 2012 Jun 8.
4. Baulac M, Leon T, O'Brien TJ, Whalen E, et al. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res. 2010 Sep;91(1):10-9. Epub 2010 Aug 8.
5. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res. 1999 Feb;33(2-3):133-43.
6. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007 Jul;48(7):1308-17.
7. Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42. Epub 2010 Sep 30.
8. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002 Sep;43(9):993-1000.
9. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010 Nov 16;75(20):1817-24. Epub 2010 Oct 13.
10. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res. 1999 Apr;34(2-3):199-205.
11. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007 Feb 6;68(6):402-8.

12. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009 Aug;50(8):1899-909. Epub 2009 Jun 1.
13. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet. 1999 Jul 3;354(9172):13-9.
14. Chiron C, Dumas C, Jambaqué I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997 Jan;26(2):389-95.
15. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010 Jun;51(6):958-67. Epub 2010 Jan 27.
16. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia. 1998 Sep;39(9):952-9.
17. Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol. 2010 Nov;25(11):1340-7. Epub 2010 Apr 19.
18. Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001 Oct 23;57(8):1416-21.
19. Faulkner MA. Perampanel: a new agent for adjunctive treatment of partial seizures. *American Journal of Health System Pharmacy*. 2014 Feb 1;71(3): 191-8.
20. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011 May 3;76(18):1555-63. Epub 2011 Mar 30.
21. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8. Epub 2008 Apr 9.
22. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141-55. Epub 2012 Nov 21.
23. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009 Mar;50(3):443-53. doi: 10.1111/j.1528-1167.2008.01951.x. Epub 2009 Jan 17.
24. Kaminow L, Schimschock JR, Hammer AE, et al. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav. 2003 Dec;4(6):659-66.
25. Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial

seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011 Oct;10(10):881-90. Epub 2011 Aug 31.
26. Lindberger M, Alenius M, Frisén L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia. 2000 Oct;41(10):1289-95.
27. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005 Nov;4(11):712-7.
28. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1773-8.
29. Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134.
30. National Institute of Neurological Disorders and Stroke. [Accessed 2013 Sept] Available from: URL: http://health.nih.gov/.
31. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011 Oct 11;77(15):1473-81. Epub 2011 Sep 28.
32. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Accessed 2014 March] Available from: http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm.
33. Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005 Nov 8;65(9):1370-5.
34. Porter RJ, Burdette DE, Gil-Nagel A, et al. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res. 2012 Aug;101(1-2):103-12. Epub 2012 Apr 16.
35. Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007 Apr 10;68(15):1197-204.
36. Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia. 2010 Oct;51(10):1970-7.
37. Verrotti A, Loiacono G, Rossi A, et al. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. *Epilepsy Research*. 2014 Jan; 108(1): 1-10.

Anti-migraine Agents – Serotonin 5-HT1 Receptor Agonists

1. Amerge [package insert]. Research Triangle Park, NC: GSK; 2013.
2. Axert [package insert]. Titusville, NJ: Janssen Pharma; 2014.
3. Frova [package insert]. Chadds Ford, PA: Endo Pharma; 2013.
4. Gold Standard, Inc. (accessed 2015 March). Clinical Pharmacology. URL: http://clinicalpharmacology.com.
5. Imitrex [package insert]. Research Triangle Park, NC: GSK; 2013.
6. Maxalt/Maxalt-MLT [package insert]. Whitehouse Station, NJ: Merck; 2011.
7. Relpax [package insert]. New York, NY: Pfizer; 2013.
8. Sumavel Dosepro [package insert]. San Diego, CA: Zogenix Inc.; 2013.
9. Treximet [package insert]. Research Triangle Park, NC: GSK; 2012.
10. Zomig/Zomig-ZMT [package insert]. Wilmington, DE: AZ; 2013.
11. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-Naproxen for Acute Treatment of Migraine; A Randomized Trial. *JAMA*. 2007;297:1443-1454.
12. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. New York: McGraw-Hill; 1999. p.1027-1028.
13. Drug Facts & Comparisons (on-line version). Central Nervous System Agents (accessed 2012 Dec) URL: http://www.efactsweb.com.
14. Electronic Orange Book. [cited 2012 Dec] http://www.fda.gov/cder/ob/default.htm.
15. Gallagher RM, Dennish G, Spierings E, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. *Headache* 2000; 40: 119-128.
16. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-“Act when Mild (AwM)”. A double-blind, placebo-controlled trial of almotriptan. *Cephalalgia.* 2008 Apr;28(4):383-91.
17. Göbel H, Winter P, Boswell D, Crisp A, Becker W, Hauge T, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. *Clin Ther* 2000; 22: 981-989.
18. Goldstein J, Keywood C. Frovatriptan for the acute treatment of migraine: a dose-finding study. *Headache* 2002; 42: 41-48.
19. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block G, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. *Headache* 1998; 38: 737-747.
20. Gruffyd-Jones K, Kies B, Middleton A, Mulder LJ, Røsjø Ømillson DS. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. *Eur J Neurol* 2001; 8: 237-245.
21. Pascual J, Vega P, Diener H-C, Allen C, Vrijens F, Patel K, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. *Cephalalgia* 2000; 20: 455-461.

22. Sandrini G, Farkkila M, Burgese G, et al. Eletriptan vs. sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. *Neurology* 2002; 59: 1210-1217.
23. Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. *Arch Neurol* 2001; 58: 944-950.
24. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, et al. Oral Rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. *Headache* 1998; 38: 748-755.

Antidepressants

1. Aplenzin [package insert]. Bridgewater, NJ: Valeant Pharma; 2014.
2. Brintellix [package insert]. Deerfield, IL: Takeda Pharma; 2014.
3. Celexa [package insert]. St. Louis, MO: Forest Labs; 2014.
4. Clinical Pharmacology. http://www.clinicalpharmacology.com/ [Accessed 2015 March].
5. Cymbalta [package insert]. Indianopolis, IN: Eli Lilly and Co; 2014.
6. Effexor [package insert]. Philadelphia, PA: Wyeth Pharma; 2012.
7. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharma; 2014.
8. Emsam [package insert]. Tampa, FL: Somerset Pharma; 2014.
9. Fetzima [package insert]. St. Loius, MO: Forest Labs, Inc.; 2014.
10. Lexapro [package insert]. St. Louis, MO: Forest Labs; 2014.
11. Luvox CR [package insert]. Palo Alto, CA: Jazz Pharma; 2014.
12. Marplan [package insert]. Parsippany, NJ: Validus Pharma; 2007.
13. Nardil [package insert]. New York, NY: Pfizer, Inc; 2007.
14. Oleptro [package insert]. Gaithersburg, MD: Angelini Pharma; 2014.
15. Parnate [package insert]. Research Triangle Park, NC: GSK; 2010.
16. Paxil [package insert]. Research Triangle Park, NC: GSK; 2014.
17. Paxil CR [package insert]. Research Triangle Park, NC: GSK; 2014.
18. Prozac [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
19. Remeron [package insert]. Whitehouse Station, NJ: Merck; 2014.
20. Sarafem [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
21. Serzone [package insert]. Princeton, NJ: BMS; 2005.
22. Viibryd [package insert]. St. Louis, MO: Forest Labs; 2014.
23. Wellbutrin [package insert]. Research Triangle Park, NC: GSK; 2014.
24. Wellbutrin SR [package insert]. Research Triangle Park, NC: GSK; 2014.
25. Wellbutrin XL [package insert]. Bridgewater, NJ: Valeant Pharma; 2014.
26. Zoloft [package insert]. New York, NY: Pfizer, Inc; 2014.
27. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. *J Clin Psychiatry*. 2005;66:94-9.

28. Ballus C, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. *Int Clin Psychopharmacol* 2000;15(1):43-8.
29. Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind 6-month treatment study. *J Clin Psychopharmacol* 2002;22(2):148-54.
30. Birkenhäger TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. *J Clin Psychiatry*. 2004 Nov;65(11):1505-10.
31. Cassano GB, Puca F, Scapicchio PL, et al. Paroxetine and fluoxetine on mood and cognitive functions in depressed nondemented elderly patients. *J Clin Psychiatry* 2002;63(5)396-402.
32. Chouinard G, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. *J Affect Disord* 1999;54(1-2):39-48. (abstract only)
33. Coleman CC, King BR, Boldne-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. *Clin Ther* 2001;23(7):1040-58.
34. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. *J Clin Psychiatry* 1998;59(7):352-7.
35. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 study group. *Ann Clin Psychiatry* 1997;9(3):157-64.
36. Davidson JR, Giller EL, Zisook S, Overall JE. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. *Arch Gen Psychiatry*. 1988 Feb;45(2):120-7.
37. Davidson JRT, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. *J Clin Psychiatry*. 1999;60(8):528-35.
38. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. *J Clin Psychiatry.* 2007 May;68(5):677-88.
39. Entsuah AR, Huang H, Thase ME. Response and remission rates on different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. *J Clin Psychiatry* 2001;62(11):869-77.
40. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. *J Clin Psychopharmacol* 2002;22(2):137-47.
41. Fava M, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. *J Clin Psychiatry* 2000;61(11):863-7.

42. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. *J Clin Psychopharmacol.* 2004;24:389-99.
43. Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. *Cochrane Database Syst Rev*. 2007 Jul 18;(3):CD004851.
44. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. *Am J Psychiatry*. 1997 Sep;154(9):1261-4.
45. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *New Engl J Med* 2000;342(20):1462-70.
46. Kroenke K, et al. Similar effectiveness of paroxetine, fluoxetine and sertraline in primary care: a randomized trial. *JAMA* 2001;286(23):2947-55.
47. Lacy CF et al (eds.). *Drug Information Handbook*. Lexi-Comp, Inc. Hudson (OH): 2000.
48. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. *J Clin Psychiatry*. 2007 Nov;68(11):1663-72.
49. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). *J Clin Psychiatry*. 2010 Feb;71(2):163-74.
50. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. *Am J Psychiatry*. 2006 Sep;163(9):1531-41.
51. Mehtonen OP, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 study group. *J Clin Psychiatry* 2000;61(2):95-100.
52. Montejo-Gonzalez, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter and descriptive clinical study of 344 patients. *J Sex Marital Ther* 1997;23(3):176-94. (abstract only)
53. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. *J Clin Psychopharmacol* 1997;17(4):267-71.
54. Newhouse PA, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. *J Clin Psychiatry* 2000;61(8)559-68.
55. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of

patients with major depressive disorder. *J Psychiatr Res*. 2008 Jan;42(1):22-34.
56. Perna G, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. *Pharmacopsychiatry* 2001;43(3):85-90. (abstract only)
57. Sifton DW (ed.). Physicians Desk Reference. Medical Economics Company, Incorporated. Montvale (NJ): 2002.
58. Suri RA, et al. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. *J Clin Psychiatry* 2000;61(12):942-6.
59. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. *Int Clin Psychopharmacol* 2003;18(3):133-41.

Antipsychotics, Second Generation, Oral

1. Abilify [package insert]. Princeton, NJ: BMS; 2014.
2. Clozaril [package insert]. East Hanover, NJ: Novartis Pharma; 2014.
3. Fanapt [package insert]. Rockville, MD: Vanda Pharma; 2014.
4. FazaClo [package insert]. Palo Alto, CA: Jazz Pharma; 2013.
5. Geodon [package insert]. New York, NY: Pfizer; 2014.
6. Invega [package insert]. Titusville, NJ: Janssen Pharma; 2014.
7. Latuda [package insert]. Marlborough, MA: Sunovion Pharma; 2013.
8. Risperdal [package insert]. Titusville, NJ: Janssen Pharma; 2014.
9. Saphris [package insert]. St. Louis, MO: Forest Labs; 2015.
10. Seroquel [package insert]. Wilmington, DE: AZ Pharma; 2013.
11. Seroquel XR [package insert]. Wilmington, DE: AZ Pharma; 2013.
12. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
13. Arato M, O'Conner R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80, 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) Study. *Int Clin Psychopharmacol.* 2002;17:207-15.
14. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. *Am J Psychiatry*. 2001;158(8):1305-13.
15. Bondolfi G, Dufour H, Patris M, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. *Am J Psychiatry*. 1998;155:499-504.
16. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *Am J Psychiatry*. 2005;162:1351-60.

17. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. *Psychopharmacology*. 2003;166:391-9.
18. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. *Am J Psychiatry*. 2001;158(5):765-74.
19. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
20. Dossenbach MRK, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. *J Clin Psychiatry*. 2001;62[suppl 2]:28-34.
21. Gomez JC, Crawford AMK. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a muticenter international trial. *J Clin Psychiatry*. 2001;62 [suppl 2]:6-11.
22. Hirsch SR, Kissling W, Bäuml J, Power A, O'Conner R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. *J Clin Psychiatr*y. 2002;63:516-23.
23. Ho BC, Miller D, Nopoulos P, Anderson NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. *J Clin Psychiatry*. 1999;60:658-663.
24. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. *Schizophr Res*. 2007 Feb;90(1-3):147-61.
25. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry*. 2002;63:763-71.
26. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. *Am J Psychiatry*. 2003;160:1651-8.
27. Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. *Am J Psychiatry*. 2003;160:741-8.
28. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. *Ann Intern Med*. 2007 Nov 6;147(9):593-602.
29. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J *Clin Psychopharmacol*. 2008 Apr;28(2):156-65.
30. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults

with bipolar depression (EMBOLDEN II). *J Clin Psychiatry*. 2010 Feb;71(2):163-74.
31. McGavin JK, Goa KL. Aripiprazole. CNS Drugs. 2002;16(11):779-86.
32. Meltzer HY, Alphs L, Green AI, Altamura C, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia. *Arch Gen Psychiatry*. 2003;60:82-91.
33. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-33.
34. Mullen J, Michael MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) Study*. Clin Ther*. 2001;23:1839-54.
35. Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. *J Affect Disord*. 2010 Jan;120(1-3):133-40.
36. Perlis RH, Baker RW, Zarate CA, Brown EB, Schuh LM, Jamal HH, et al. Olanzapine versus risperidone in the treatment of manic or mixed stated in bipolar I disorder: a randomized, double-blind trial. *J Clin Psychiatry*. 2006;67:1747-53.
37. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. *Arch Gen Psychiatry*. 2003;60:681-90.
38. Rosenheck R, Perlick K, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. *JAMA*. 2003;290(20):2693-702.
39. Sharif ZA, Raza A, Ratakonda SS. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. *J Clin Psy*chiatry. 2000;61:498-504.
40. Shea S, Turgay A, Carroll A, Schulz M, Orlik H Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. *Pediatrics*. 2004;114:e634-41.
41. Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. *Int J Clin Pract*. 2003;57(1):49-54.
42. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, et al. Efficacy of olanzapine in acute bipolar mania. *Arch Gen Psychiatry*. 2000;57:841-9.
43. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients

clinically eligible for treatment with clozapine. *Biol Psychiatry*. 2001;49:52-63.
44. Tran PV, Hamilton SH, Kuntz BS, Potvin JH, Anderson SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol.* 1997;17:407-18.
45. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia and schizoaffective disorder. *Am J Psychiatry*. 2002;159:255-262.
46. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. *Int Clin Psychopharmacol.* 2007 Nov;22(6):363-70.

Antipsychotics, Second Generation/SSRI Combination

1. Prozac [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
2. Symbyax [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
3. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
4. Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen, ME, et al. A 7-week, randomized double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. *J Clin Psychiatry*. 2006;67:1025-33.
5. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2007 Feb;68(2):224-36.
6. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry*. 2003;60:1079-88.

Attention Deficit Hyperactivity Disorder Agents

1. Adderall [package insert]. Wayne, PA: Shire US Inc.; 2014.
2. Clinical Pharmacology [accessed 2015 March] http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Daytrana [package insert]. Miami, FL: Noven Pharma; 2013.
4. Focalin XR [package insert]. East Hanover, NJ; Novartis Pharma; 2013.
5. Intuniv [package insert]. Wayne, PA: Shire US Inc.; 2014.
6. Kapvay [package insert]. Atlanta, GA: Shionogi Pharma Inc.; 2014.
7. Metadate CD [package insert]. Smyrna, GA: UCB Inc.; 2013.
8. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Co., 2014.
9. Vyvanse [package insert]. Wayne, PA: Shire US Inc.; 2015.
10. Average Wholesale Price. FirstDataBank, update December 2002.

11. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. *Pediatrics* 2002; 110(2): 258-266.
12. Drug Facts and Comparisons. CNS Stimulants. [cited 2013 April] http://www.efactsweb.com.
13. Efron D, Jarmen F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. *Pediatrics* 1997; 100(6): 1-7.
14. Electronic Orange Book. [cited 2013 April] http://www.fda.gov/cder/ob/default.htm.
15. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. 2008 Jan;69(1):149-59.
16. James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. *American Academy of Child and Adolescent Psychiatry* 2001; 40(11): 1268-1276.
17. Kratochvil C, Heiligenstein J, Dittman R et al. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. *J Am Acad Child Adolesc Psychiatry* 2002;41(7):776-784.
18. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. *Biol Psychiatry* 2003;53:112-120.
19. Michelson D, Allen A, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with Attention Deficit Hyperactivity Disorder: A randomized, placebo-controlled study. *Am J Psychiatry* 2002;159:1896-1901.
20. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with ADHD: A randomized, placebo-controlled, dose response study. *Pediatrics* 2001;108(5):e83
21. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. *Am J Psychiatry* 2008;165:721-30.
22. Pelham WE, Aronoff H, Midlam JK, et al. A comparison of Ritalin and Adderall: Efficacy and time-course in children with attention-deficit/hyperactivity disorder. *Pediatrics* 1999; 103(4): 1-14.
23. Pliszka SR, Browne RG, Olvera RL, Wynne SK. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. *American Academy of Child and Adolescent Psychiatry* 2000; 39(5): 619-626.

24. Swanson JM, Wigal S, Greenhill LL, et al. Analog classroom assessment of Adderall in children with ADHD. *American Academy of Child and Adolescent Psychiatry* 1998; 37(5): 519-526.
25. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 2001 Apr;21(2):223-8.
26. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. *Archives of General Psychiatry* 1999; 56: 1073-1086.
27. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. *Journal of Attention Disorders* 2005; 9(1): 275-289.
28. Wolraich ML, Greenhill LL, Pelham WE, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. *Pediatrics* 2001; 108(4): 883-892.

Fibromyalgia Agents

1. Clinical Pharmacology. http://www.clinicalpharmacology-ip.com/Default.aspx [Accessed 2015 March].
2. Cymbalta [package insert]. Indianopolis, IN: Eli Lilly and Co; 2014.
3. Lyrica [package insert]. New York, NY: Pfizer, Inc; 2013.
4. Savella [package insert]. St. Louis, MO: Forest Labs; 2015.
5. Arnold LM, Clauw D, Wang F, et al. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *The Journal of Rheumatology*. 2010 Dec;37(12):2578-86.
6. Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism*. 2010 Sep;62(9):2745-56.
7. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism*. 2005 Apr;52(4):1264-73.
8. Mease PJ, Clauw DJ, Gentreau RM, et al. The Efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *The Journal of Rheumatology*. 2009 Feb;36(2):398-409.
9. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. *The Journal of Rheumatology*. 2008 Mar;35(3):502-14.
10. National Institute of Arthritis and Musculoskeletal and Skin Diseases. http://www.niams.nih.gov [Accessed 2013 April].

11. Pharmacist Letter. www.pharmacistletter.com [Accessed 2015 March].

Medication Assisted Treatment Agents

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Suboxone [package insert]. Richmond, VA: Reckitt Benckiser Pharma, Inc.; 2014.
3. Subutex [package insert]. Richmond, VA: Reckitt Benckiser Pharma, Inc.; 2014.
4. Zubsolv [package insert] Orexo US, Inc.; 2014.
5. Electronic Orange Book. [cited 2013 Sept] http://www.fda.gov/cder/ob/default.htm.
6. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. *JAMA*. 1992 May 27;267(20):2750-5.
7. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. *J Nerv Ment Dis*. 1993 Jun;181(6):358-64.
8. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psychiatry*. 1996 May;53(5):401-7.
9. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial *Lancet* 2008; 371: 2192–2200.
10. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. *Am J Psychiatry*. 2005 Feb;162(2):340-9.
11. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. *Arch Gen Psychiatry.* 1997 Aug;54(8):713-20.
12. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *Am J Psychiatry.* 1994 Jul;151(7):1025-30.

Multiple Sclerosis Agents

1. Ampyra [package insert]. Hawthorne, NY: Acorda Therapeutics, Inc.; 2013.
2. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2014.
3. Avonex [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2014.
4. Betaseron [package insert]. Wayne, NJ: Bayer HealthCare Pharma; 2014.
5. Clinical Pharmacology [Accessed 2015 March]. http://www.clinicalpharmacology-ip.com/Default.aspx.

6. Copaxone [package insert]. Kansas City, MO: Teva Neuroscience Inc.; 2014.
7. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, Inc.; July 2009.
8. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, Inc.; 2014.
9. Plegridy [package insert]. Cambridge, MA: Biogen Idec; 2014.
10. Rebif [package insert]. Rockland, MA: Serono, Inc.; December 2015.
11. Tecfidera [package insert]. Cambridge, MA: Biogen Idec Inc.; 2014.
12. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase-3, double-blind study. *Lance Neurol* 2014; 13(7):657-65.
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):402-15. Epub 2010 Jan 20.
14. Durelli L, Verdun E, Barbero P, et al and Independent Comparison of Interferon Trial Study Group (INCOMIN). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 1-year prospective randomized mulicentre study (INCOMIN). *Lancet* 2002;359:1453-60.
15. Electronic Orange Book. [cited 2013 April] http://www.fda.gov/cder/ob/default.htm.
16. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. *Lancet* 1998;352(9139):1491-7.
17. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med* 2012;367(12):1098-107.
18. Jacobs LD, Beck RW, Simon JH. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. *N Engl J Med* 2000;343(13):898-904.
19. Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. *Eur J Neurol* 2001;8(2):141-8
20. Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. *Multiple Sclerosis* 2001;7(6):349-53.
21. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med* 2011;365(14):1293-303.

22. Panitch H, Goodin D.S. Francis G. et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trail. *Neurology* 2002;59:1496-1506
23. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. *Lancet* 1998;352:1498-504
24. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002;59:802-8.

Neuropathic Pain Agents

1. Clinical Pharmacology [accessed 2015 March]. Available from: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Gralise [package insert]. Menlo Park, CA; Depomed Inc.; 2013.
3. Lidoderm [package insert]. Chadds Ford, PA; Endo Pharma; 2014.
4. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. *Curr Med Res Opin.* 2004;20 Suppl 2: S21-8.
5. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010 Sep;17(9):1113-e88. Epub 2010 Apr 9.
6. Chandra K, Shafiq N, Pandhi P, et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. *Int J Clin Pharmacol Ther* 2006 Aug;44(8):358-63.
7. de Leon-Casasola, O. (2011), New Developments in the Treatment Algorithm for Peripheral Neuropathic Pain. *Pain Medicine* 12: S100–S108. doi: 10.1111/j.1526-4637.2011.01160.x
8. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. *Eur J Pain* 2005 Oct;9(5):543-54. Epub 2004 Dec 18.
9. Drug Facts and Comparisons. [accessed 2013 Sept]. Available from: http://online.factsandcomparisons.com/index.aspx.
10. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. *Mayo Clin Proc* 2010 Mar;85(3 Suppl):S3-14.
11. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (http://www.fda.gov/cder/ob/default.htm), accessed September 2013.
12. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. *Clin J Pain* 2002 Sep-Oct;18(5):297-301.

13. Gatti A, Sabato AF, Occhioni R, et al. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. *Eur Neurol* 2009;61(3):129-37. Epub 2008 Dec 18.
14. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. *Lancet* 2009 Oct 10;374(9697):1252-61. Epub 2009 Sep 30.
15. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. *N Engl J Med* 2005 Mar 31;352(13):1324-34.
16. Grosskopf J, Mazzola J, Wan Y, et al. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. *Acta Neurol Scand* 2006 Sep;114(3):177-80.
17. Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. *J Pain Symptom Manage* 2007 Aug;34(2):183-9. Epub 2007 Jun 28.
18. Leijon G, Boivie J.Central post-stroke pain--a controlled trial of amitriptyline and carbamazepine. *Pain* 1989 Jan;36(1):27-36.
19. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. *Arch Intern Med* 1999 Sep 13;159(16):1931-7.
20. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. *Am J Med* 2009 Oct;122(10 Suppl):S22-32.
21. Rowbotham MC, Reisner LA, Davies PS, et al. Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial. *J Pain* 2005 Nov;6(11):741-6.
22. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. *Neurology* 2003 Apr 22;60(8):1284-9.
23. Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. *Mayo Clin Proc* 2011 Jul;86(7):615-26.
24. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. *Neurology* 2008 Apr 29;70(18):1630-5. Epub 2007 Nov 14.

Parkinson's Agents

1. Apokyn [package insert]. Morristown, NJ: Vernalis Pharma; 2014.
2. Azilect [package insert], Kansas City, MO: Teva Pharma; 2014.
3. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.

4. Comtan [package insert], East Hanover, NJ: Novartis; 2015.
5. Eldepryl [package insert], Tampa, FL: Somerset Pharma; 1998.
6. Mirapex [package insert], Ridgefield, CT: Boehringer Ingelheim Pharma; 2013.
7. Mirapex ER [package insert]. Ridgefield, CT: Boehringer Inhelheim Pharma; 2014.
8. Parcopa [package insert], Eden Prairie, MN: Cima Labs Inc.; 2006.
9. Requip [package insert], Research Triangle Park, NC: GSK; 2014.
10. Requip XL [package insert], Research Triangle Park, NC: GSK; 2014.
11. Sinemet [package insert], Princeton, NJ: BMS; 2014.
12. Sinemet CR [package insert] Princeton, NJ: BMS; 2014.
13. Stalevo [package insert], East Hanover, NJ: Novartis; 2014.
14. Tasmar [package insert], Aliso Viejo, CA: Valeant Pharma; 2013.
15. Zelapar [package insert], Costa Mesa, CA: Valeant Pharma; 2014.
16. Facts and Comparisons. E-facts [cited 2013 Sept]. http://www.efactsweb.com.
17. Koller WC, Thomas HJ, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. *Neurology*. 1999 Sept 22; 53(5):1012-1019.
18. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. *JAMA.* 2000 Oct 18;284(15):1931-8.
19. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. *Lancet.* 2005; Mar 12-18;365(9463):947-54.
20. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann *Neurol*. 2010 Jul;68(1):18-27.
21. The Entacapone to Tolcapone Switch Study Investigators. Entacapone to Tolcapone Switch: Multicenter Double-Blind, Randomized, Active-Controlled Trial in Advanced Parkinson's Disease. *Movement Disorders* 2007; 22(1):14–19.
22. Whone AL, Watts RL, Stoess AJ, et al. Slower Progression of Parkinson's Disease with Ropinirole versus Levodopa: The REAL-PET Study. *Ann Neurol* 2003;54:93–101.

Restless Legs Syndrome Agents

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Horizant [package insert]. Research Triangle Park, NC: GSK; 2013.
3. Mirapex [package insert], Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2013.
4. Neupro [package insert]. Smyrna, GA: UCB, Inc.; 2015.
5. Requip [package insert], Research Triangle Park, NC: GSK; 2014.

6. Facts and Comparisons. E-facts [cited 2013 Sept]. http://www.efactsweb.com.
7. Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. *J Clin Sleep Med*. 2011 Jun 15;7(3):282-92.
8. Manconi M, Ferri R, Zucconi M, et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. *Mov Disord.* 2011 Apr;26(5):892-5. Epub 2011 Mar 2.

Sedative-Hypnotics, Non-Barbiturate

1. Ambien [package insert]. Bridgewater, NJ: Sanofi-Aventis LLC; 2014.
2. Ambien CR [package insert]. Bridgewater, NJ: Sanofi-Aventis LLC; 2014.
3. Belsomra [package insert]. Whitehouse Station, NJ: Merck; 2014.
4. Clinical Pharmacology [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Dalmane [package insert]. Aliso Viejo, CA: Valeant Pharma; 2009.
6. Edluar [package insert]. Somerset, NJ: Meda Pharma; 2014.
7. Halcion [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Company; 2014.
8. Intermezzo [package insert]. Port Richmond, CA: Transcept Pharma; 2013.
9. Lunesta [package insert]. Marlborough, MA: Sepracor Inc; 2014.
10. ProSom [package insert]. North Chicago, IL: Abbott; 2004.
11. Rozerem [package insert]. Deerfield, IL: Takeda Pharma; 2010.
12. Silenor [package insert]. San Diego, CA: Somaxon Pharma; 2010.
13. Sonata [package insert]. Bristol, TN: King Pharma; 2013.
14. Zolpimist [package insert]. Flemington, NJ: NovaDel Pharma, Inc; 2008.
15. Allain H, Bentue-Ferrer D, Breton SL, et al. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. *Hum Psychopharmacol* 2003; 18:369-74.
16. Ancoli-Isreal S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. *Sleep Med* 2005; 6:107-13.
17. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. *Sleep* 2003; 26:793-9.
18. McEvoy GK, Litvak K, Welsh OH, Snow EK, Dewey DR, editors. AHFS Drug Info. Bethesda (MD): *American Society of Health-System Pharmacists*; 2006.
19. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. *JAMA* 1999; 281:991-9.

20. Oude Voshaar RC, van Balkom AJLM, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. *Eur Neuropsychopharmacol* 2004; 14:301-6.
21. Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. *J Clin Psychiatry* 2004; 65:1128-37.
22. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. *Sleep*. 2005; 28:303-7.
23. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. *Sleep*. 2005; 28:720-7.
24. Takahashi T, Okajima Y, Otsubo T, et al. Comparison of hangover effects among triazolam, flunitrazepam and quazepam in healthy subjects: a preliminary report. *Psychiatry Clin Neurosci* 2003; 57:303-9.
25. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. *J Clin Psychopharmacol* 2000; 20:328-37.
26. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Electronic Orange Book. Available at: http://www.fda.gov/cder/ob/default.htm [last accessed 9/8/2009]
27. Vermeeren A, Riedel WJ, van Boxtel MPJ, et al. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. *Sleep* 2002; 25:224-31.
28. Vester JC, Volkerts EE, Schreuder AHC, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. *J Clin Psychopharmacol* 2002; 22:576-83.
29. Walsh JK, Pollaj CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. *Clin Neuropharmacol* 2000; 23: 17-21.
30. Wolters Kluwer Health, Inc. Facts and Comparisons 4.0, © 2006. Available at: http://online.factsand comparisons.com/. [last accessed 5/12/06].

Skeletal Muscle Relaxants, Non-Benzodiazepine

1. Amrix [package insert]. Frazer, PA: Cephalon Inc.; 2013.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Norgesic Forte [package insert]. St. Paul (MN): 3M Pharma; 1996.
4. Skelaxin [package insert]. Bristol, TN; King Pharma; 2008.
5. Soma [package insert]. Somerset, NJ; Meda Pharma; 2013.
6. Soma Compound [package insert]. Somerset, NJ: Meda Pharma; 2013.

7. Zanaflex [package insert]. Hawthorne, NY: Acorda Therapeutics, Inc.; 2013.
8. Borenstein DG, Korn S. Efficacy of a Low-Dose Regimen of Cyclobenzaprine Hydrochloride in Acute Skeletal Muscle Spasm: Results of Two Placebo-Controlled Trials. *Clinical Therapeutics*. 2003; 1056-1073.
9. Covington T, Berardi R, Young L et al eds. Handbook of nonprescription drugs. Washington, DC: AphA; 1996.
10. Delgado J and Remers W eds. Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. 9th ed. New York, NY: JB Lippincott Company; 1991.
11. Dirckx J ed. Stedman's concise medical dictionary for health professionals. 3rd ed. Dayton, Ohio: Williams & Wilkins; 1997.
12. Drug Facts and Comparisons. Skeletal Muscle Relaxants. [cited 2013 Sept] http://www.efactsweb.com.
13. Electronic Orange Book. [cited 2013 Sept] http://www.fda.gov/cder/ob/default.htm.
14. Gelber D, Good D, Dromerick A et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. *Stroke*. 2001; 1847-1846
15. Lacy CF, et al (eds.). Drug Information Handbook, 13th edition. Lexi-Comp, Inc. Hudson (OH): 2005-2006.
16. Nance P, Bugaresti J, Shellenberger K et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. *Neurology.* 1994; S44-S52.
17. Smith C, Birnbaum G, Carter J et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. *Neurology*. 1994; S34-S43.
18. Turturro M, Frater C, D'Amico F. Cyclobenzaprine With Ibuprofen Versus Ibuprofen Alone in Acute Myofascial Strain: A Randomized, Double-Blind Clinical Trial. *Annals of Emergency Medicine*. 2003; 818-826.

Smoking Deterrents

1. Clinical Pharmacology [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Chantix [package insert]. New York, NY: Pfizer Inc.; 2014.
3. Nicoderm CQ [patient information]. GlaxoSmithKline, Inc. Available at: www.nicodermcq.com. [cited 2012 April].
4. Nicorette [patient information]. GlaxoSmithKline, Inc. Available : www.nicorette.com. [cited 2012 April].
5. Nicotrol Inhaler [package insert]. NY, NY: Pfizer Inc.; 2006.
6. Nicotrol Nasal Spray [package insert]. NY, NY: Pfizer, Inc.; 2010.
7. Zyban [package insert]. Research Triangle Park (NC): GSK; 2014.
8. American Cancer Society, Inc. Cigarette Smoking. [cited 2012 Aug] www.cancer.org.

9. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society; 2012.
10. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax.* 2008 Aug;63(8):717-24.
11. Centers for Disease Control and Prevention. Cigarette smoking - attributable mortality and years of potential life lost - United States, 1990. MMWR 1993;42:645-649.
12. Drug Facts and Comparisons 4.0. Smoking Deterrents [cited 2013 Sept] http://www.efactsweb.com.
13. Electronic Orange Book. [cited 2013 Sept] http://www.fda.gov/cder/ob/default.htm.
14. Gonzales D, Rennard SI, Nides M et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006; 296(1): 47-55.
15. Hajek P, West R, Foulds J et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. *Arch Intern Med* 1999; 159: 2033-2038.
16. Jorenby D, Leischow S, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *New England Journal of Medicine* 1999; 340(9): 685-691
17. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006; 296(1): 56-63.
18. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. Hudson, Ohio: Lexi-Comp, Inc; 2001.
19. Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. Cigarette smoking among adults - United States, 1994. MMWR 1996; 45(27): 588-590.
20. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry.* 2009 Nov;66(11):1253-62.
21. Shiffman S, Dresler C, Hajek P et al. Efficacy of nicotine lozenge for smoking cessation. *Arch Intern Med* 2002; 162: 1267-1276.
22. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med*. 2009 Dec 14;169(22):2148-55.
23. Tonstad S, Tonnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA* 2006; 296(1): 64-71.
24. US Department of Health and Human Services. Treating tobacco use and dependence. A clinical practice guideline. 2008 Update [cited 2009 March] www.guideline.gov.

Endocrine Agents

Diabetes – Amylin Analogs, Incretin Mimetics, and Insulins

1. Apidra [package insert]. Bridgewater, NJ: Sanofi-Aventis LLC; 2013.
2. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2014.
3. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2011.
4. Clinical Pharmacology. [Accessed 2015 March]. Available from URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2013.
6. Lantus [package insert]. Kansas City, MO: Sanofi-Aventis LLC; 2013.
7. Levemir [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc; 2013.
8. Symlin [package insert]. San Diego, CA: Amylin Pharma, Inc; 2008.
9. Tanzeum [package insert]. Wilmington, DE: GSK; 2014.
10. Trulicity [package insert]. Indianapolis, IN: Eli Lilly; 2014.
11. Victoza [package insert]. Princeton, NJ: Novo Nordisk Pharma, Inc; 2013.
12. Bergenstall RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet.* 2010 Aug 7;376(9739):431-9.
13. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004; 27(11): 2628-35.
14. Dailey G, Rosenstock J, Moses R, et al. Insulin Glulisine Provides Improved Glycemic Control in Patients with Type 2 Diabetes. *Diabetes Care* 2004; 27:2363-2368.
15. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005; 28(5): 1092-100.
16. Garg S, Rosentstock J, Ways K. (Abstract) Optimized Basal-bolus insulin regimens in type 1 diabetes: Insulin Glulisine versus Regular Human Insulin in Combination with Basal Insulin Glargine. *Endocr Pract*. 2005;11(1):11-17.
17. Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. *Diabetes Care* 2002;25(5):883-888.
18. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. *Obesity Research* 2004; 12(4): 661-8.
19. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in

patients with type 2 diabetes: a 1-year randomized controlled trial. *Diabetes Care* 2003; 26(3): 784-90.
20. Home P, Bartley P, Russell-Jones D, et al. Insulin Detemir Offers Improved Glycemic Control Compared with NPH Insulin in People with Type 1 Diabetes. *Diabetes Care* 2004;27:1081-1087.
21. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 2005; 28(5): 1083-91.
22. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care.* 2009; 32(1):193-203.
23. Orange book. Available at: www.fda.gov/cder/ob/default.htm.
24. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet.* 2010 Apr 24;375(9724):1447-56.
25. Raskin P, Klaff L, Bergenstal, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. *Diabetes Care* 2000; 23(11): 1666-1671.
26. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type I diabetes mellitus: a 1-year, randomized controlled trial. *Diabetic Medicine* 2004; 21(11): 1204-12.
27. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. *Diabetes Technology and Therapeutics* 2002; 4(1): 51-61.
28. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. *Diabetes Metab Res Rev* 2006; 22(6): 483-91.
29. Roach P, Strack T, Arora V, et al. Improved glycemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. *International Journal of Clinical Practice* 2001; 55(3): 177-182.
30. Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. *Clinical Therapeutics* 1999;21(3):523-534.
31. Roach P, Yue L, Arora V, et al. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. *Diabetes Care* 1999;22(8):1258-1261.

32. Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes. *Diabetes Care* 2001;24(4):631-636.
33. Zinman B, Ross S, Campos RV, et al. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. *Diabetes Care* 1999;22(4):603-608.

Diabetes – Oral Hypoglycemics

1. Actos [package insert]. Deerfield, IL: Takeda Pharma; 2013.
2. Amaryl [package insert]. Bridgewater, NJ: Sanofi-Aventis LLC; 2013.
3. Avandamet [package insert]. Research Triangle Park, NC: GSK; 2012.
4. Avandia [package inert]. Research Triangle Park, NC: GSK; 2012.
5. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
6. Duetact [package insert]. Deerfield, IL: Takeda Pharma; 2013.
7. Farxiga [package insert]. Princeton, NJ: AZ-BMS; 2014.
8. Glucotrol XL [package insert]. New York, NY: Pfizer, Inc; 2008.
9. Glucovance [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2008.
10. Glynase PresTab [package insert]. New York, NY: Pfizer, Inc; 2008.
11. Glyset [package insert]. New York, NY: Pfizer, Inc; 2008.
12. Invokana [package insert]. Titusville, NJ: Janssen Pharma; 2013.
13. Invokamet [package insert]. Titusville, NJ: Janssen Pharma; 2014.
14. Janumet [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2013.
15. Janumet XR [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2013.
16. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2013.
17. Jardiance [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2014.
18. Jentadueto [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2013.
19. Kazana [package insert]. Deerfield, IL: Takeda Pharma; 2013.
20. Kombiglyze [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
21. Metaglip [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2008.
22. Nesina [package insert]. Deerfield, IL: Takeda Pharma; 2013.
23. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2013.
24. Oseni [package insert]. Deerfield, IL: Takeda Pharma; 2013.
25. Prandimet [package insert]. Princeton, NJ: Novo Nordisk Inc; 2012.
26. Prandin [package insert]. Princeton, NJ: Novo Nordisk, Inc; 2008.
27. Precose [package insert]. West Haven, CT: Bayer Corporation; 2008.
28. Starlix [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2008.
29. Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012.

30. Xigduo XR [package insert]. Wilmington, DE: AZ-BMS; 2014.
31. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet 2010 Aug 7;376(9739):431-9.
32. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 2003;290(4):486-94.
33. Damsbo P, Caluson P, Marbury TC, et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. *Diabetes Care* 1999;22:789-794.
34. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;345:363-403.
35. Dills DG, Schneider J and The Glimepiride/glyburide research group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. *Horm Metab Res* 1996;28:426-429.
36. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. *JAMA* 2000;283:1695-1702.
37. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate release metformin to a once-daily extended-release formulation. *Clinical Therapeutics* 2003;25(2):515-29.
38. Garber AJ, Donovan DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism* 2003;88(8):3598-604.
39. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care* 2005; 28(7): 1547-54.
40. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. *Clinical Therapeutics* 2003;25(3):890-903.
41. Hoffmann J, Spengler M, et al. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients: the Essen II study. *Am J Med* 1997;103(6):483-490.
42. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. *Diabetes Care* 2001;24:983-988.
43. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing

mealtime glucose levels in type 2 diabetes. *Diabetes Care* 2000;23:1660-1665.
44. Inzucchi SE. Oral antihyperlgycemic therapy for type 2 diabetes. *JAMA* 2002;287(3):360-372.
45. Johnston PS, Feig PU, Coniff RE, et al. Chronic treatment of African-American type 2 diabetic patients with α-glucosidase inhibition. *Diabetes Care* 1998;21(3):416-422.
46. Jovanovic L, Dailey G, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. *J Clin Pharmacol* 2000;40:49-57.
47. NAVIGATOR Study Group, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 Apr 22;362(16):1463-76.
48. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet 2010 Apr 24;375(9724):1447-56.
49. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. *Diabetes Care* 1998;21(12):2050-2055.
50. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. *Diabetes Care* 2004: 27(6):1265-70
51. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy in unsuccessful. J *Clin Pharmacol* 1998;38:636-641.
52. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Int Med* 2001;16(3):397-405.
53. Turner RC, Cull CA, Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus, progressive requirement for multiple therapies (UKPDS 49). *JAMA* 1999;281(21):2005-2012.
54. UK Prospective Diabetes Study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854-65.
55. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet* 1998;352:837-53.
56. Wolffenbuttel BHR, Landgraf R, Dutch and German Repaglinide Study Group. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. *Diabetes Care* 1999;22:463-467.

57. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. *Ann Intern Med* 1999;130:389-396.

Estrogenic Agents

1. Activella [package insert] Princeton, NJ; Novo Nordisk; 2013.
2. Alora [package insert] Morristown, NJ; Watson Pharma; 2009.
3. Angeliq [package insert] Wayne, NJ; Bayer Healthcare Pharmaceuticals; 2012.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Combipatch [package insert] East Hanover, NJ; Novartis Pharmaceuticals; 2013.
6. Divigel [package insert] Minneapolis, MN; Upsher-Smith Laboratories, Inc.; 2012.
7. Duavee [package insert]. Philadelphia, PA; Wyeth Pharma Inc.; 2013.
8. Elestrin [package insert] Philadelphia, PA; Azur Pharma; 2014.
9. Enjuvia [package insert] Pomona, NY; Duramed Pharmaceuticals, Inc.; 2007.
10. Estrace Cream [package insert] Rockaway, NJ; Warner-Chilcott LLC; 2008.
11. Estrace Oral [package insert] Rockaway, NJ; Warner-Chilcott LLC; 2008.
12. Estrasorb [package insert] Bristol, TN; Graceway Pharmaceuticals, LLC; 2008.
13. Estring [package insert] New York, NY; Pharmacia & Upjohn Company; 2008
14. Evamist [package insert] St. Louis, MO; Ther-Rx Corporation; 2011.
15. Femhrt [package insert] Rockaway, NJ; Warner-Chilcott LLC; 2005.
16. Femring [package insert] Rockaway, NJ; Warner-Chilcott LLC; 2009.
17. Femtrace [package insert] Rockaway, NJ; Warner-Chilcott LLC; 2009.
18. Menest [package insert] Bristol, TN; Monarch Pharmaceuticals; 2005.
19. Menostar [package insert] Wayne, NJ; Bayer HealthCare Pharmaceuticals; 2007.
20. Mimvey [package insert] Sellersville, PA; Teva Pharmaceuticals; 2009.
21. Ortho™ Dienestrol Cream [package insert]. East Hanover, NJ; Ortho McNeil; 1998.
22. Prefest [package insert] Pomona, NY; Duramed Pharmaceuticals, Inc.; 2007.
23. Premarin Oral Tablets [package insert] Philadelphia, PA; Wyeth Pharmaceuticals Inc.; 2010.
24. Premarin Vaginal Cream [package insert] Philadelphia, PA; Wyeth Pharmaceuticals Inc.; 2012.
25. Premphase [package insert] Philadelphia, PA; Wyeth Pharmaceuticals Inc.; 2012.

26. Prempro [package insert] Philadelphia, PA; Wyeth Pharmaceuticals Inc.; 2012.
27. Vagifem [package insert] Princeton, NJ; Novo Nordisk Pharmaceuticals Inc.; 2012.
28. Vivelle-Dot [package insert] East Hanover, NJ; Novartis Pharmaceuticals; 2004.
29. Anderson GL, Limacher M, Assaf AR, et. al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004 Apr 14;291(14):1701-12.
30. Archer DF, Furst K, Tipping D, et. al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999 Oct;94(4):498-503.
31. Bachmann G, Lobo RA, Gut R, et al. Efficacy of Low-Dose Estradiol Vaginal Tablets in the Treatment of Atrophic Vaginitis: A Randomized Controlled Trial. Obstet Gynecol. 2008 Jan;111(1):67-76.
32. Barrett-Conner A, Young R, Notelovitz M, et. al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999 Dec;44(12):1012-20.
33. Chlebowski RT, Anderson GL, Gass M, WHI Investigators, et. al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010 Oct 20;304(15):1684-92.
34. Dickerson J, Bressler R, Christian C. Efficacy of estradiol vaginal cream in postmenopausal women. *Clinical Pharmacology and Therapeutics* 1979;26:502-507.
35. Dirckx J ed. Stedman's concise medical dictionary for the health professions. 3rd ed. Dayton, Ohio: Williams & Wilkins; 1997.
36. Drug Facts and Comparisons 2012. [cited 2012 Aug] Available from: http://www.efactsweb.com.
37. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. *American Journal of Obstetrics and Gynecology* 1999;180:1072-9.
38. Foster DC, Palmer M and Marks J. Effect of vulvovaginal estrogen on sensorimotor response of the lower genital tract: a randomized controlled trial. *Obstetrics & Gynecology* 1999;94:232-237.
39. Gallagher JC, Fowler SE, Detter JR, et. al. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001 Aug;86(8):3618-28.
40. Girdler SS, Hinderliter AL, Wells EC, et. al. Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects. Obstet Gynecol 2004 Jan;103(1):169-80.

41. Good WR, John VA, Ramirez M, et. al. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group. Climacteric 1999 Mar;2(1):29-36.
42. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003 May 21;289(19):2525-33.
43. Harris ST, Eriksen EF, Davidson M, et. al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001 May;86(5):1890-7.
44. Johnson JV, Davidson M, Archer D, et. al. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause 2002 Jan-Feb;9(1):16-22.
45. Kornafel KL and March CM. Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety. *Southern Medical Journal* 1992;85:270-273.
46. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. Hudson, Ohio: Lexi-Comp, Inc; 2001.
47. Messinger-Rapport B and Thacker H. Prevention for the older woman. A practical guide to hormone replacement therapy and urogynecologic health. *Geriatrics* 2001; 56:32-4,37-8,40-2.
48. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. *Fertility and Sterility* 1994;61:178-180.
49. Place VA, Powers M, Darley PE, et. al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985 Aug 15;152(8):1092-9.
50. Rioux JE, Devlin C, Gelfand M, et al. 17beta-estradiol vaginal tablets versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. *Menopause* 2000;7:156-161. *Abstract.*
51. Ritenbaugh C, Stanford JL, Wu L, et. al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008 Oct;17(10):2609-18.
52. Rohan TE, Negassa A, Chlebowski RT, et. al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008 Apr 16;100(8):563-71.
53. Rossouw JE, Anderson GL, Prentice RL, et. al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 Jul 17;288(3):321-33.
54. Simon HA, Liu JH, Speroff L, et. al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate

and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003 Jan;188(1):92-9.
55. Simon JA, Symons JP, FemHRT Study Investigators. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause 2001 Sep-Oct;8(5):321-7.
56. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for the relief of menopausal symptoms. *Obstetrics & Gynecology* 2003;102(4):823-34.
57. Utian WH, Speroff L, Ellman H, et. al. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause 2005 Nov-Dec;12(6):708-15.
58. Wasnich RD, Bagger YZ, Hosking DJ, et. al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004 Nov-Dec;11(6 Pt 1):622-30.
59. White WB, Hanes V, Chauhan V, et. al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006 Aug;48(2):246-53.

Growth Hormones

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Genotropin [package insert]. New York, NY: Pfizer; 2012.
3. Humatrope [package insert]. Indianapolis, IN: Eli Lilly; 2011.
4. Norditropin [package insert]. Princeton, NJ: Novo Nordisk, 2013.
5. Nutropin [package insert]. San Francisco, CA: Genentech, 2012.
6. Nutropin AQ [package insert]. San Francisco, CA: Genentech, 2012.
7. Omnitrope [package insert]. Princeton, NJ: Sandoz, 2011.
8. Saizen [package insert]. Rockland, MA: EMD Serono, 2012.
9. Serostim [package insert]. Rockland, MA: EMD Serono, 2012.
10. Tev-Tropin [package insert]. North Wales, PA: Gate Pharmaceuticals, 2011.
11. Zorbtive [package insert]. Rockland, MA: EMD Serono, 2004.
12. Ari M, Bakalov VK, Hill S, et al. The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner Syndrome. *J Clin Endocrinol Metab* 2006 Nov; 91(11): 4302-5.
13. Carel JC, Chatelain P, Rochiccioli P, et al. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. *J Clin Endocrinol Metab* 2003 Apr; 88(4): 1587-93.
14. Craig ME, Cowell CT, Larsson P, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer

International Growth Database). *Clin Endocrinol* 2006 Aug; 65(2): 178-85.
15. Dacou-Voutetakis C, Karavanaki-Karanassiou K, Petrou V, et al. The growth pattern and final height of girls with Turner Syndrome with and without growth hormone treatment. *Pediatrics* 1998; 101:663-668.
16. Darendeliler F, Ranke MB, Bakker B, et al. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database). *Horm Res* 2005; 63(1): 40-7.
17. Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. *N Engl J Med* 2000 Sept; 343(13): 923-30.
18. Hokken-Koelega A, Mulder P, De Jong R, et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. *Pediatr Nephrol* 2000 Jul; 14(7): 701-6.
19. Orange book. Accessed at www.fda.gov/cder/ob/default.htm March 2009.
20. Pasquino AM, Pucarelli I, Segni M, et al. Adult height in sixty girls with Turner Syndrome treated with growth hormone matched with an untreated group. *J Endocrinol Invest* 2005; 28: 350-356.
21. Radetti G, Pasquino B, Gottardi E, et al. Insulin sensitivity in Turner's syndrome: influence of GH treatment. *Eur J Endocrinol* 2004; 151: 351-354.
22. Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. *J Clin Endocrinol Metab* 2006 Jun; 91(6): 2047-54.
23. U.S. Food and Drug Administration. Accessed at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ Mar 2015.

Osteoporosis – Bone Ossification Enhancers

1. Actonel [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals; 2013.
2. Atelvia [package insert]. Rockaway; NJ: Warner Chilcott; 2013.
3. Boniva [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2013.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Didronel [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals; 2013.
6. Fortical [package insert]. Minneapolis, MN: Upsher-Smith Laboratories; 2011.
7. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2013.

8. Fosamax Plus D [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2013.
9. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet* 1996;348:1535-1541.
10. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA* 2006; 296(24): 2927-38.
11. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: to prevent recurrence of osteoporotic fractures study. *The American Journal of Medicine* 2000;109:267-276.
12. Chesnut III CH. Skag A. Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *Journal of Bone & Mineral Research*. 2004;19(8):1241-9.
13. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. *Journal of the American Medical Association* 1999;282:1344-1351.
14. Hosking D, Adami S, Felsenberg D, et. al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. *Current Med Research and Opinion* 2003;19(5):383-94. (abstract).
15. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. Hudson, Ohio: Lexi-Comp, Inc; 2006.
16. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *New England Journal of Medicine* 1995;333:1437-1443.
17. Marcus R, Wong M, Heath H, & Stock J. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. *Endocrine Reviews* 2002;23:16-37.
18. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. *New England Journal of Medicine* 2001;344:333-340.
19. Miacalcin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2014.
20. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. *The American Journal of Medicine* 1999;106:513-520.
21. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. *Menopause* 2002;9:84-101.

22. Orwoll ES, Brinkley NC, Lewiecki EM, et al. Efficacy and safety of monthly ibandronate in men with low bone density. *Bone.* 2010 Apr;46(4):970-6.
23. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. *Journal of Clinical Endocrinology and Metabolism* 1996;81:961-967.

Gastrointestinal Agents

Anti-Emetic Agents

1. Anzemet [package insert]. Bridgewater, NJ; Sanofi-Aventis: September 2013.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Emend Capsules [package insert]. Whitehouse Station, NJ; Merck & Co, Inc.; 2013.
4. Emend for Injection [package insert]. Whitehouse Station, NJ; 2013.
5. Sancuso [package insert]. Bedminster, NJ; ProStrakan Inc., 2011.
6. Zofran Tablets/ODT/Solution [package insert]. Research Triangle Park, NC; GlaxoSmithKline; 2013.
7. Zuplenz [package insert]. Woodcliff Lake, NJ; Par Pharmaceutical Inc.; 2013.
8. 5-HT_3 antagonists. In: Hebel SK, ed. Drug Facts and Comparisons, St. Louis: Facts & Comparisons, Inc., 2002.
9. Campos D, Pereira RJ, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. *Journal of Clinical Oncology* 2001;19(6):1759-1767.
10. Davidson N, Rapoport B, Erikstein B. et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. *Clinical Therapeutics* 1999;21(3):492-502.
11. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT_3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. *Cancer* 2003; 98(11): 2473-2482.
12. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. *European Journal of Cancer* 1996;32A(9):1532-9
13. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following

moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron [Abstract]. *Annals of Oncology* 2003; 14(10): 1570-1577.
14. Gralla RJ, Navari, RM, Hesketh, PJ. et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for hightly emetogentic cisplatin-based chemotherapy. *Journal of Clinical Oncology* 1998;16(4):1568-1573.
15. Hesketh PJ, grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—The Aprepitant Protocol 052 Study Group. *Journal of Clinical Oncology* 2003; 21(22): 4112-4119.
16. Kovac AL, Scuderi PE, Boerner TF, et al. Treatment of post operative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. *Anesthesiology and Analgesia* 1997;85:546-52.
17. Lofters WS, Pater JL, Zee B. et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. *Journal of Clinical Oncology* 1997;15(8):2966-2973.
18. Perez EA, Hesketh P, Sandbach J. et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. *Journal of Clinical Oncology* 1998;16(2):754-760.
19. Rubenstein EB, Gralla, RJ, Hainsworth, JD, et al. Randomized, double blind, dose-response trial, cross four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. *Cancer* 1997;79:1216-24.
20. The Italian group for antiemetic research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. *New England Journal of Medicine* 2000;342(21):1554-9.

Chronic Constipation Agents

1. Amitiza [package insert]. Bethesda, MD: Sucampo Pharma; 2013.
2. Gold Standard, Inc (accessed 2015 March). Clinical Pharmacology. URL:http://clinicalpharmacology.com.
3. Linzess [package insert]. Cambridge, MA: Ironwood Pharma; 2013.
4. Johnson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride Channel Activator, in Patients With Chronic Constipation. *Am J Gastroenterol* 2008;103:170–177).

5. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. *N Engl J Med* 2011 Aug 11;365(6):527-36.
6. Medline (accessed 2013 Dec): available at http://www.nlm.nih.gov/medlineplus/.

Pancreatic Enzymes

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Creon [package insert]. Marietta, GA; Solvay Pharma; 2011.
3. Drug Facts and Comparisons 2011 Digestive Enzymes. [Accessed 2011 May]. Available from: URL: http://www.efactsweb.com.
4. Pancreaze [package insert]. Titusville, NJ: Janssen; 2014.
5. Pertzye [package insert]. Bethlehem, PA: Digestive Care Inc.; 2012.
6. Ultresa [package insert]. Birmingham, AL: Aptalis Pharma US Inc.; 2012.
7. Viokace [package insert]. Birmingham, AL: Aptalis Pharma US Inc.; 2012.
8. Zenpep [package insert]. Yardley, PA; Eurand Pharmaceuticals, Inc.; 2013.
9. Stern RC, Eisenberg JD, Wagener JS, et al. A Comparison of the Efficacy and Tolerance of Pancrelipase and Placebo in the Treatment of Steatorrhea in Cystic Fibrosis Patients With Clinical Exocrine Pancreatic Insufficiency. *Am J Gastroenterol.* 2000 Aug;95(8):1932-8.
10. Williams J, MacDonald A, Weller PH, et al. Two enteric coated microspheres in cystic fibrosis. *Archives of Disease in Childhood* 1990; 65: 594-597.

Proton Pump Inhibitors

1. Aciphex [package insert]. Titusville, NJ: Eisai and Janssen Pharmaceutica, Inc; 2013.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Dexilant [package insert]. Deerfield, IL: Takeda Pharma; 2013.
4. Nexium [package insert]. Wilmington, DE: AZ Pharma; 2014.
5. Prevacid [package insert]. Deerfield, IL: Takeda Pharma; 2012.
6. Prilosec Capsule/Suspension [package insert]. Wilmington, DE: AZ Pharma; 2014.
7. Protonix [package insert]. Philadelphia, PA: Wyeth Laboratories; 2013.
8. Corinaldest R, Valentini M, Belaiche J, Colin R, Geldof H. et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European muticentre study. *Aliment Pharmacol Ther* 1995; 9:667-71.
9. Dekkers CPM, Beker JA, Thjobleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. *Aliment Pharmacol Ther* 1999; 13:179-86.

10. Electronic Orange Book. [cited 2011 March] http://www.fda.gov/cder/ob/default.htm.
11. Farley A, Wruble LD, Humphries TJ, et al. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. *Am J Gatroenterol* 2000; 95:1894-99.
12. Gelman CR, Moore MB, Hutchinson TA, editors: DRUGDEX® System. MICROMEDEX, Inc., Englewood, (CO) (Online Edition [2009]).
13. Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. *Aliment Pharmacol Ther* 26, 1101–1111.
14. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. *Am J Gastroenterol* 2001; 96:27-34.
15. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. *Aliment Pharmacol Ther* 2000; 14:1249-58.
16. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs. ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. *Arch Fam Med* 2000; 9:624-630.
17. Khuroo MS, Yattoo GN, Javid G, Khan BA, Shah AA, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. *N Engl J Med* 1997; 336:1054-58.
18. Koop H, Schepp W, Dammann HG, Schneider A, Luhmann R, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. *J Clin Gastroenterol* 1995; 20:192-5.
19. Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P, et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. *Am J Gastroenterol* 1994; 89:1191-9.
20. Lanza F, Goff J, Silvers, Winters J, Jhala N, Jennings D, Greski-Rose P, et al. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. *Dig Dis Sci* 1997; 42:2529-36.
21. McEvoy GK, Litvak K, Welsh OH, Snow EK, Dewey DR, editors. AHFS Drug Info. Bethesda (MD): American Society of Health-System Pharmacists; 1999.
22. McFarland RJ, Bateson MC, Green JRB, O'Donoghue DP, Dronfield MW, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. *Gastroenterol* 1990; 98:278-83.

23. Okai T, Sawabu N, Songur Y, Motoo Y, Watanabe H. Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. *J Clin Gastroenterol* 1995; 20(Suppl 2):S32-S35.
24. Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatmentof acute duodenal ulceration – a multicentre study. *Aliment Pharmacol Ther* 1995; 9:411-16.
25. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. *Arch Intern Med* 2000; 160:1803-09.
26. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. *Am J Gastroenterol* 2001; 96:656-65.
27. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. *Ann Intern Med* 1996; 124:859-67.
28. Robinson M, Sahba B, Avner D, Jhalas N, Greski-Rose PA, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. *Aliment Pharmacol Ther* 1995; 9:25-31.
29. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. *Dig Dis Sci* 2000; 45:845-53.
30. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. *Dig Dis Sci* 1988:523-29.
31. Walker K. Wyeth-Ayerst Pharmaceuticals (written communication). September 2001.
32. Witzel L, Gutz H, Huttemann W, Schepp W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. *Aliment Pharmacol Ther* 1995; 9:19-24.

Ulcerative Colitis Agents

1. Apriso [package insert]. Morrisville, NC: Salix Pharma; 2008.
2. Asacol [package insert]. Cincinnati (OH): Procter & Gamble Pharma; 2013.
3. Asacol HD [package insert]. Cincinnati (OH): Procter & Gamble Pharma; 2013.
4. Canasa [package insert]. Birmingham (AL): Axcan Pharma, Inc.; 2013.
5. Clinical Pharmacology [Accessed 2015 March]. Available from: http://www.clinicalpharmacology-ip.com/Default.aspx.
6. Colazal [package insert] Morrisville (NC): Salix Pharma; 2008.
7. Delzicol [package insert]. Rockaway, NJ: Warner Chilcott; 2013.
8. Dipentum [package insert]. Marietta, GA: Alaven Pharma; 2009.
9. Giazo [package insert]. Morrisville, NC: Salix Pharma, Inc.; 2012.

10. Lialda [package insert]. Wayne (PA): Shire US, Inc.; 2013.
11. Rowasa [package insert]. Marietta, GA: Alaven Pharma; 2008.
12. Pentasa [package insert]. Wayne (PA): Shire US, Inc.; June 2013.
13. Courtney MG, Nunes DP, Bergin CF, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. *Lancet.* 1992; 339(8804): 1279-81.
14. Crohn's and Colitis Foundation of America. [Accessed 2012 March]. Available at: http://www.ccfa.org/info/about/ucp.
15. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. *Am J Gastroenterol.*1993; 88(8): 1188-97.
16. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. *Am J Gastroenterol.*2005; 100(11): 2478-85.
17. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can *J Gastroenterol.* 2007 Dec;21(12):827-34.
18. Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. *Inflamm Bowel Dis.* 2005; 11(7): 625-30.
19. Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. *Am J Gastroenterol.*2002; 97(6): 1398-407.
20. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. *Dig Dis Sci.* 1995; 40(2): 296-304.
21. National Digestive Diseases Information Clearinghouse (NDDIC). [Accessed 2012 March]. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/.
22. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. *Am J Gastroenterol.*2002; 97(12): 3078-86.
23. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. *BMJ* 1989; 298(6666): 82-6.
24. Robinson M, Hanauer S, Hoop R, et al. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. *Aliment Pharmacol Ther.* 1994; 8(1): 27-34.
25. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. *Gastroenterology.* 2009 Dec;137(6):1934-43.e1-3. Epub 2009 Sep 18.

26. Schroeder KW, Tremaine WJ, Ilstrup DM, et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med.* 1987; 317(26): 1625-9.
27. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. *Ann Intern Med.* 1991; 115(5): 350-5.
28. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. *Gastroenterology* 1987; 92(6): 1894-8.

Genitourinary Agents

Benign Prostatic Hyperplasia Agents

1. Avodart [package Insert]. Research Triangle Park, NC: GSK; 2013.
2. Cardura [package insert]. New York, NY: Pfizer, Inc; 2013.
3. Cardura XL [package insert]. New York, NY: Pfizer, Inc; 2011.
4. Clinical Pharmacology [Accessed 2015 March] Available at: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Flomax [package insert]. North Chicago, IL: Boehringer Ingelheim; 2011.
6. Hytrin [package insert]. North Chicago, IL: Abbott Labs; 2009.
7. Jalyn [package insert. Research Triangle Park, NC: GSK; 2013.
8. Minipress [package insert]. New York, NY: Pfizer, Inc; 2013.
9. Proscar [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2014.
10. Rapaflo [package insert]. Corona, CA: Watson Pharma; 2013.
11. Uroxatral [package insert]. Bridgewater, NJ: Sanofi-Aventis LLC; 2013.
12. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction : A prospective, randomized, controlled study. *J Urology* 2003;169:2253-2256.
13. Bendix Holme J, Christensen MM, Rasmussen PC, et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. *Scand J Urol Nephrol* 1994; 28(1):77-82.
14. Buzelin JM, Fonteyne E, Knoturri M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). *Br J Urol* 1997; 80(4):597-605.
15. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride, and the combination of both in the treatment of benign prostatic hyperplasia. *Eur Urol* 1998; 34(3):169-75.
16. Hansen BJ, Meyhoff HH, Nording J, et al. Placebo effects on the pharmacological treatment of uncomplicated benign prostatic hyperplasia. *Scand J Urol Nephrol* 1996; 30(5):373-7.

17. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *JAMA* Nov 2006; 296(19): 2319-28.
18. Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009 Dec;182(6):2825-30.
19. Lepor H, Williford WO, Barry, MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. *NEJM* 1996; 335(8):533-9.
20. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. *Urology* 1998; 51(6):901-6.
21. McConnell JD, Roehrborn CG, Bautisa OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benigh prostatic hyperplasia. *New Engl J Med* 2003; 349:2387-2398.
22. Na YJ, Guo YL, Gu FL. Clinical comparison of selective and non-selective alpha 1a-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. *J Med* 1998; 29(5-6):289-304.
23. Narayan P, Evans C, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. *J Urology* 2003;170:498-502.
24. O'Leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5-α-reductase inhibitor. *BJU Internat* 2003;92:262-266.
25. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
26. Roehrborn CG, Kerrebroeck PV, and J. Nordling. Safety and efficacy of alfuzosin 10mg once daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. *BJU Internat* 2003;92:257-261.
27. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study; a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. *Urology* 1996; 47(2):159-68.
28. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. *Urology* 2001; 58(6):953-9.
29. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men

with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010 Jan;57(1):123-31.
30. Thompson IM, Goodman PJ, Tangen CM. et al. The influence of finasteride on the development of prostate cancer. *New Engl J Med* 2003;349(3):213-222.
31. Thorpe A, Neal D. Benign prostatic hyperplasia. *Lancet* 2003;361:1359-1367.
32. Tsujii T. Comparison of prazosin, terazosin, and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized, multicenter study. *Int J Urol* 2000; 7(6):199-205.

Electrolyte Depleters

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Eliphos [package insert]. Madison, MS: Hawthorn Pharma; 2007.
3. Fosrenol [package insert]. Wayne, PA: Shire; 2012.
4. Phoslo [package insert]. Boca Raton, FL: Nabi Biopharma; 2011.
5. Phoslyra [package insert]. Waltham, MA: Fresenius Medical; 2011.
6. Renagel [package insert]. Cambridge, MA: Genzyme; 2011.
7. Renvela [package insert]. Cambridge, MA: Genzyme; 2011.
8. Velphoro [package insert]. Waltham, MA: Fresenius Medical; 2013.
9. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int*. 2005; 68(4): 1815-24.
10. Chertow GM, Raggi P, McCarthy JT, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. *Am J Nephrol.* 2003; 23(5): 307-14.
11. Finn WF, Joy MS, Hladik G, et al. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. *Clin Nephrol*. 2004; 62(3): 193-201.
12. Joy MS, Finn WF, et al. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. *Am J Kidney Dis*. 2003; 42(1): 96-107.
13. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). *Kidney Int*. 2004; 65(5): 1914-26.
14. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. *J Heart Valve Dis*. 2004; 13(1): 134-41.

Urinary Antispasmodics

1. Clinical Pharmacology [Accessed 2015 March]. Available from: http://www.clinicalpharmacology.com.

2. Detrol/Detrol LA [package insert]. New York, NY: Pfizer, Inc; 2012.
3. Ditropan [package insert]. Raritan, NJ: Ortho-McNeil Pharma; 2012.
4. Ditropan XL [package insert]. Raritan, NJ: Ortho-McNeil Pharma; 2013.
5. Enablex [package insert]. East Hanover, NJ: Novartis Pharma; 2012.
6. Gelnique [package insert]. Corona, CA: Watson Pharma; 2012.
7. Myrbetriq [package insert]. Northbrook, IL: Astellas Pharma Inc.; 2012.
8. Oxytrol [package insert]. Corona, CA: Watson Pharma, Inc; 2012.
9. Sanctura [package insert]. Irvine, CA: Allergan, Inc; 2012.
10. Sanctura XR [package insert]. Irvine, CA: Allergan, Inc; 2012.
11. Toviaz [package insert]. New York, NY: Pfizer, Inc; 2012.
12. Urispas [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2001.
13. Vesicare [package insert]. Paramus, NJ: Yamanouchi Pharma America, Inc. and GlaxoSmithKline; 2013.
14. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. *J Urology* 1999; 161:809-1812.
15. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. *Mayo Clin Proceedings* 2001; 76:358-363.
16. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. *Urology* 1997; 6A Suppl:90-6; discussion 97-9. (Abstract)
17. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstructions: A prospective, randomized, controlled study. *J Urology* 2003; 169(6):2253-2256.
18. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind, placebo-controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. *J Urology* 2004; 172(5 Pt 1):1919-24.
19. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. *Eur Urol* Sep 2005; 48(3): 464-70.
20. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. *BJU Int* 2004; 93(3):303-10.
21. Couture JA, Valiquette L. Urinary incontinence. *Annal Pharmacol* 2000; 34: 646-55.
22. Davilla GW, Daugherty CA, Sanders SW, et al. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to

immediate release oral oxybutynin treatment of patients with urge urinary incontinence. *J Urology* 2001; 166(1):140-145.
23. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. *Mayo Clinic Proceedings* 2003; 78(6):687-695.
24. Dmochowski RR, Davilla GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. *J Urology* 2002; 168(2):580-586.
25. Drug Therapeutics Bulletin 2001; 39(8):59-64.
26. Haab F, Stewart L. Dwyer P. Darifenacin, and M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. *Eur Urol* 2004; 45(4):420-9; discussion 429.
27. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010 Jan;105(1):58-66.
28. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *JAMA* Nov 2006; 296(19): 2319-28.
29. Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. *JMCP* 2002; 8(5):343-52.
30. Orange book. Available from: www.accessdata.fda.gov/scripts/cder/ob/docs.
31. *Pharmacist Letter* April 2003. New Drug: Oxytrol (oxybutynin transdermal system). Detailed- Document #190411.
32. Staskin D, Dmochowski R, Sand P et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. *J Urol* 2009;181: 1764-1772.
33. Stewart K, McGhan WF, Offerdahl T, et al. Overactive bladder patients and the role of the pharmacist. *J APhA* 2002; 42(3):469-478.
34. The Office of Women's Health of the US Department of Health and Human Services. The public health implications of urogenital disease: a focus on overactive bladder. *Clinician* 2003; 21(4):1-19.
35. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. *Urology* 2001; 57(3):414-21.
36. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. *J Urology* 2002; 168:1897-1913.
37. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. *J Urology* 2004; 171(6 Pt1):2311-5.

Immunomodulators

Immunomodulators for Systemic Inflammatory Disease

1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.
2. Cimzia [package insert]. Smyrna, GA: UCB, Inc; 2012.
3. Clinical Pharmacology. [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
4. Cosentyx [package insert]. East Hanover, NJ: Novartis; 2015.
5. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; 2013.
6. Humira [package insert]. North Chicago, IL: Abbott; 2014.
7. Kineret [package insert]. Thousand Oaks, CA: Amgen Inc; 2013.
8. Orencia [package insert]. Princeton, NJ: BMS; 2013.
9. Simponi [package insert]. Horsham, PA: Centocor Ortho Biotech Inc; 2010.
10. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis. [Accessed 2009 September] Available from: URL: http://www.rheumatology.org.
11. Arthritis Foundation. [Accessed 2012 May] Available from: URL: http://www.arthritis.org.
12. Breedveid FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006; 54(1): 26-37.
13. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2002; 46(3): 614-24.
14. Keystone E, van der Heijde D, Mason D et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. *Arthritis Rheum* 2008;58(11):3319-29.
15. Keystone E, Genovese M, Klareskog L et al. Golimumab, a human antibody to tumor necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789–796.
16. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. *Lancet* 2004; 363(9410): 675-81.

Oral Immunosuppressants – Class Under Review

Infectious Disease Agents

Cephalosporins – Oral

1. Cedax [package insert]. Alpharetta, GA: Sciele Pharma, Inc; 2002.
2. Ceftin [package insert]. Research Triangle Park, NC: GSK; 2007.
3. Cefzil [package insert]. Princeton, NJ: BMS; 2007.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Duricef [package insert]. Princeton, NJ: BMS; 2007.
6. Keflex [package insert]. Germantown, MD: Middlebrook Pharma; 2008.
7. Omnicef [package insert]. North Chicago, IL: Abbott Laboratories; 2008.
8. Spectracef [package insert]. Cary, NC: Cornerstone Therapeutics, Inc; 2008.
9. Suprax [package insert]. Baltimore, MD: Lupin Pharma; 2007.
10. Vantin [package insert]. New York, NY: Pfizer, Inc; 2007.
11. Asmar BI, Dajani AS, Del Beccaro MA et al. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. *Pediatrics.* 1994;94:847-52
12. Drehobl M, Bianchi P, Constance H et al. Comparison of cefdinir and cefaclor in the treatment of community-acquired pneumonia. *Antimicrobial Agents Chemother.* 1997;41(7):1579-1583
13. Fogarty CM, Bettis RB, Griffin TJ et al. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. *J Antimicrob Chemother.* 2000;45:851-858.
14. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012 Feb 8;307(6):583-9.
15. Leigh AP, Nemeth MA, Keyserling CH et al. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. *Clin Ther.* 2000;22(7):818-825.
16. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *Clinical Infectious Diseases* 2007 44:S27-72.
17. Nemeth MA, McCarthy J, Gooch WM et al. Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. *Clin Ther.* 1999;21(11):1873-1881.
18. Paster ZR, McAdoo AM, Keyserling CH et al. A comparison of five-day regimen of cefdinir with a seven-day regime of loracarbef of the treatment of acute exacerbations of chronic bronchitis. *Int J Clin Pract.* 2000; 54(5):293-299
19. Pessey J, Gehanno P, Thoroddsen E et al. Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized

multicenter comparison with amoxicillin/clavulanate. *Pediatr Infect Dis J.* 1999;18(10):854-859
20. Phillips H, Van Hook CJ, Butler T et al. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults. *Chest.* 1993;104(5):1387-92
21. Pichichero ME, Gooch WM, Rodriguez W et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. *Arch Pediatr Adolesc Med.* 1994;148:1053-1060
22. Stevens DL, Pien F, Drehobl M. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. *Diagn Microbiol Infect Dis.* 1993;16(2):123-129
23. Tack KJ, Keyserling CH, McCarty J et al. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. *Antimicrobial Agents Chemothe.* 1997;41(4):739-742
24. Tack KJ, Littlejohn TW, Maillous G et al. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. *Clin Ther.* 1998;20(2):244-256.

Macrolides – Oral

1. Biaxin [package insert]. North Chicago, IL: Abbott Labs; 2008.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. E.E.S [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
4. Ery-Ped [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
5. Erythrocin Lactobionate [package insert]. Lake Forest, IL: Hospira; 2012.
6. PCE [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
7. Zithromax [package insert]. New York, NY: Pfizer Labs; 2007.
8. Zmax [package insert]. New York, NY: Pfizer Labs; 2012.
9. Arguedas A, Loaiza C, Rodriguez F, et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media. *J Chemother* 1997;9(1):44-50.
10. Dunne M, Fessel J, Kumar P, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated *Mycobacterium avium* infection in patients with human immunodeficiency virus. *Clin Infect Dis* 2000;31(5):1245-52.
11. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH et al. Randomised placebo controlled multicenter trial to assess short term clarithromycin for patients with stable coronary heart disease; CLARICOR trial. *BMJ* 2006 Jan 21;332 (7534):151.
12. Jorgensen DM. Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A beta-hemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: a double-blind, double-dummy study. Clin Microbiol Infect 2009 Dec;15(12):1103-10.

13. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single-blind trial. *Pediatr Infect Dis J* 2001;20(12):1149-54.
14. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *Clinical Infectious Diseases* 2007 44:S27-72.
15. Marple BF, Roberts CS, Frytak JR, et al. Azithromycin extended release vs amoxicillin/clavulanate: symptom resolution in acute sinusitis. Am J Otolaryngol 2010 Jan-Feb;31(1):1-8.
16. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. *Eur J Clin Microbiol Infect Dis* 1998;17(12):828-33.
17. Venuta A, Laudizi L, Beverelli A, et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. *J Int Med Res* 1998;26(3):152-8.
18. Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. *Pediatr Infect Dis J* 1999;18(2):98-104.

Quinolones – Oral

1. Avelox [package insert]. West Haven, CT: Bayer Corporation; 2008.
2. Cipro [package insert]. West Haven, CT: Bayer Corporation; 2008.
3. Clinical Pharmacology. [Accessed 2015 March] http://www.clinicalpharmacology-ip.com/Default.aspx.
4. Factive [package insert]. Waltham, MA: Oscient Pharmaceuticals; 2008.
5. Levaquin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2008.
6. Noroxin [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2008.
7. ProQuin XR [package insert]. Menlo Park, CA: Depomed, Inc; 2008.
8. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. *Clin. Infect Dis.* 2006 Jan 1;42(1):73-81.
9. Dunbar LM. Wunderink RG. Habib MP. et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis* 2003;37(6):752-60.
10. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012 Feb 8;307(6):583-9.
11. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *Clinical Infectious Diseases* 2007 44:S27-72.

12. Sethi S. Fogarty C. Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. *Resp Med* 2004; 98(8):697-707(abstract).
13. Wilson R. Allegra L, Huchon G. et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. *Chest* 2004;125(3):811-3.

Antibiotics, Inhaled – Class Under Review

Antifungals for Onychomycosis & Systemic Infections

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Diflucan [package insert]. New York, NY: Pfizer, Inc; 2008.
3. Gris-Peg [package insert]. Farmingdale, NY: Pedinol Pharma, Inc; 2007.
4. Lamisil [package insert]. East Hanover, NJ : Novartis Pharma; 2007.
5. Noxafil [package insert]. Kenilworth, NJ: Schering Corp; 2006.
6. Penlac [package insert]. Bridgewater, NJ: Dermik Labs; 2004.
7. Sporanox [package insert]. Titusville, NJ : Janssen Pharma; 2012.
8. Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. *British Medical Journal* 1995;311: 919-922.
9. Chapman SW, Bradsher RW, Campbell D et al. Practice guidelines for the management of patients with blastomycosis. *Clin Infect Dis* 2000;30: 679-83.
10. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007: 356(4): 348-59.
11. Dismukes W. Introduction to antifungal drugs. *Clin Infect Dis* 2000;3: 653-657.
12. Elewski BE, Caceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. *Journal of the American Academy of Dermatology*: 59(1):41-54.
13. Evans EGV, Sigurgeirsson B for the LION study group. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. *British Medical Journal* 1999;318: 1031-1035.
14. Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guidelines for the treatment of coccidioidomycosis. *Clin Infect Dis* 2000;30: 658-61.
15. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double blind trial. Mycoses study group. *Ann Intern Med* 2000;133(9): 676-86.

16. Kauffman CA, Hajjeh R & Chapman W. Practice guidelines for the management of patients with sporotrichosis. *Clin Infect Dis* 2000;30 684-87.
17. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. Hudson, Ohio: Lexi-Comp, Inc; 2005.
18. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 2000;30: 662-78.
19. Saag MS, Graybill RG, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. *Clin Infect Dis* 2000;30: 710-18.
20. Sobel JD for the mycoses study group. Practice guidelines for the treatment of fungal infections. *Clin Infect Dis* 2000; 30:652.
21. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by aspergillus. *Clin Infect Dis* 2000;30: 696-709.
22. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007: 356(4): 335-47.
23. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. *Clinical Infectious Diseases* 2006: 42(8): 1179-86.
24. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. *Clin Infect Dis* 2000;30: 688-95.

Antivirals - Hepatitis C

1. Clinical Pharmacology. [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Copegus [package insert]. Nutley, NJ: Roche Pharma; 2013.
3. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2014.
4. Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.
5. Pegasys [package insert]. Nutley, NJ: Roche Pharma; 2013.
6. PEG-Intron [package insert]. Kenilworth, NJ: Schering Corporation; 2013.
7. Rebetol [package insert]. Kenilworth, NJ: Schering Corporation; 2013.
8. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2013.
9. Viekira Pak [package insert]. North Chicago, IL: Abbvie, Inc.; 2014.
10. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2004; 292(23): 2839-48.
11. Fried MS, Shiffman, ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347(13)975-82.
12. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1

hepatitis C: the randomized PILLAR study. *Hepatology* 2013 Dec;58(6):1918-29.
13. Gentile I, Borgia G. Ledipasvir/sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin coadministration or length of treatment. *Evidence-based medicine* 2014 Dec;19(6):223-4.
14. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* 2013 May 16;368(20):1867-77.
15. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotype 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. *The Lancet Infectious Diseases* 2013 May;13(5):401-8.
16. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. *Hepatology*. 2001; 34:395-403.
17. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Eng J Med*. 1998; 339(21):1485-1492.
18. Sharma P. Sofosbuvir-based antiviral therapy for treatment naïve hepatitis C genotypes 1, 2, and 3. *Gastroenterology* 2013 Jul;145(1):245-7.
19. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004; 351(5): 438-50.
20. Zeuzem S, Feinman, SV, Rasenack J, et al. Peginteferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 2000;343:1666-72.
21. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. *Gastroenterology* 2014 Feb;146(2): 430-41.

Antivirals – Herpes

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Famvir [package insert]. East Hanover, NJ: Novartis Pharma; 2012.
3. Valtrex [package insert]. Research Triangle Park, NC: GSK; 2008.
4. Zovirax [package insert]. Research Triangle Park, NC: GSK; 2008.
5. Chosidow O, Drouault, Y, Levonte-veyriac F, et al. Famciclovir vs. acyclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. *Br J Dermatol* 2001;144:818-824.
6. Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* 2004;350(1):11-20.

7. Diaz-Mitoma F, Sibbald RG, Sharfran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes- a randomized controlled trial. *JAMA* 1998;280(10):887-892
8. Gnann JW, Whitley RJ. Clinical practice: Herpes zoster. *N Engl J Med* 2002;347(5):340-345.
9. Ioannidis JP, Collier AC, Cooper DA, et al. clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. *J Infect Dis* 1998;178:349-59.
10. Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. *AIDS* 2000;14(9):1211-7.
11. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. *Arch Fam Med* 2000;9(9):863-9.
12. Tyring SK, Douglas JM, Corey L, et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. *Arch Dermatol* 1998;134:185-191.
13. Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. *Ann Pharmacother* 2002;36:1525-31.
14. Whitley RJ, Roizman B. Review: Herpes simplex virus infections. *Lancet* 2001;357:1513-18.
15. Workowski KA, Levine WC, Wasserhelt JN. U.S. Center for disease control and prevention guidelines for the treatment of sexually transmitted disease: an opportunity to unify clinical and public health practice. *Ann Intern Med* 2002;137:255-262.

Antivirals – HIV, Protease Inhibitors

1. Clinical Pharmacology. [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology.com/.
2. Drugs@FDA. [Accessed 2015 March] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.*N Engl J Med*. 2001 Aug 9;345(6):398-407.
4. Antiretroviral Treatment of Adult HIV Infection. 2010 Recommendations of the International AIDS Society – USA Panel. *JAMA*. 2010;304(3):321-333.
5. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. *Curr HIV Res*. 2012 Mar;10(2):171-81.

6. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. *J Infect Dis*. 2003 Sep 1;188(5):635-42. Epub 2003 Aug 20.
7. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. *Antivir Ther*. 2005;10(6):735-43.
8. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. *Lancet*. 2006 Aug 5;368(9534):476-82.
9. Eron JJ, Young B, Cooper DA,et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet*. 2010 Jan 30;375(9712):396-407.
10. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. *AIDS*. 2004 Jul 23;18(11):1529-37.
11. Gulick RM, Smeaton LM, D'Aquila RT, et al. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. *J Infect Dis*. 2001 Mar 1;183(5):715-21. Epub 2001 Jan 30.
12. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30; 312(4): 410-25.
13. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. *AIDS*. 2003 Jun 13;17(9):1339-49.
14. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. *Lancet*. 2006 Aug 5;368(9534):466-75.
15. Katzenstein TL, Kirk O, Pedersen C, et al. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. *J Infect Dis*. 2000 Sep;182(3):744-50. Epub 2000 Aug 3.
16. Kumar PN, Salvato P, Lamarca A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48

weeks (ESS100327, the ACTION Study). *AIDS Res Ther*. 2009 Apr 9;6:3. doi: 10.1186/1742-6405-6-3.
17. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. *Lancet*. 2007 Jul 7;370(9581):49-58.
18. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. *AIDS*. 2009 Aug 24;23(13):1679-88.
19. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. *Lancet*. 2008 Aug 23;372(9639):646-55.
20. National Institute of Allergy and Infectious Disease. [Accessed 2013 May] Available from: URL: http://health.nih.gov/.
21. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Accessed 2013 May] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm.
22. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. *AIDS*. 2008 Jul 31;22(12):1389-97.
23. Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. *HIV Clin Trials*. 2009 Mar-Apr;10(2):76-87.
24. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med*. 2008 May 15;358(20):2095-106.
25. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med*. 2003 Dec 11;349(24):2293-303.
26. Salazar JC, Cahn P, Yogev R, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. *AIDS*. 2008 Sep 12;22(14):1789-98.
27. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. *J Acquir Immune Defic Syndr*. 2003 Jan 1;32(1):18-29.
28. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med*. 2003 Dec 11;349(24):2304-15.
29. Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil

fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. *Antivir Ther*. 2011;16(3):339-48.
30. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *N Engl J Med*. 1999 Dec 16;341(25):1865-73.
31. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. *JAMA*. 2001 Mar 7;285(9):1155-63.
32. Tashima KT, Bausserman L, Alt EN, et al. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. *HIV Clin Trials*. 2003 Jan-Feb;4(1):29-36.
33. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. *N Engl J Med*. 2002 Jun 27;346(26):2039-46.
34. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. *J Acquir Immune Defic Syndr*. 2009 Apr 1;50(4):367-74.

Antivirals – HIV, Reverse Transcriptase Inhibitors

1. Atripla [package insert]. Princeton, NJ: Bristol-Myers Squibb and Foster City, CA: Gilead Sciences; 2013.
2. Complera [package insert]. Foster City, CA: Gilead Sciences; 2013.
3. Edurant [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2012.
4. Emtriva [package insert]. Foster City, CA: Gilead Sciences; 2013.
5. Epivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
6. Epzicom [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
7. Rescriptor [package insert]. Vega Baja, PR: Pfizer Pharmaceuticals; 2012.
8. Retrovir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
9. Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2012.
10. Trizivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
11. Truvada [package insert]. Foster City, CA: Gilead Sciences; 2012.
12. Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
13. Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012.
14. Viramune XR [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012.
15. Viread [package insert]. Foster City, CA: Gilead Sciences; 2013.
16. Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2012.

17. Ziagen [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
18. Bonnet M, Bhatt N, Baudin E, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomized, non-inferiority trial. *Lancet Infect Dis*. 2013 April;13(4): 303-12.
19. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. *Lancet*. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.
20. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. *Lancet*. 1996 Aug 3;348(9023):283-91.
21. Friedland GH, Pollard R, Griffith B, et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. *J Acquir Immune Defic Syndr*. 1999 Aug 1;21(4):281-92.
22. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. *J Infect Dis*. 2005 Dec 1;192(11):1921-30. Epub 2005 Oct 25.
23. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. *N Engl J Med*. 2004 Apr 29;350(18):1850-61.
24. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30; 312(4): 410-25.
25. Intelence [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2013.
26. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. *AIDS* 2009; 23:2289.
27. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. *Lancet* 2007; 370:39.
28. Lowenthal ED, Ellenburg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. *JAMA*. 2013 May;309(17): 1803-9.
29. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. *Lancet* 2007; 370:29.

30. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. *Lancet*. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.
31. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. *Lancet*. 2004 Apr 17;363(9417):1253-63.
32. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. *AIDS*. 2005 Mar 25;19(5):463-71.

Antivirals – HIV, Integrase Strand Transfer Inhibitors

1. Clinical Pharmacology. [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology.com/.
2. Drugs@FDA. [Accessed 2015 March] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Antiretroviral Treatment of Adult HIV Infection. 2010 Recommendations of the International AIDS Society – USA Panel. *JAMA*. 2010;304(3):321-333.
4. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet*. 2013 Aug; 382(9893): 700-8.
5. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. *Lancet*. 2012 Jun 30;379(9835):2429-38.
6. DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. *HIV Clin Trials*. 2012 Jul-Aug;13(4):228-32.
7. Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMARK studies: final results of two randomized, placebo-controlled trials. *Lancet Infect Dis*. 2013 Jul; 13(7): 587-96.
8. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet*. 2010 Jan 30;375(9712):396-407. Epub 2010 Jan 12.

9. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. *Lancet Infect Dis*. 2011 Dec;11(12):907-15. Epub 2011 Sep 18.
10. Gallien S, Braun J, Delaugerre C, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. *J Antimicrob Chemother.* 2011 Sep;66(9):2099-106. Epub 2011 Jun 28.
11. Gotuzzo E, Markowitz M, Ratanasuwan W, et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). *J Acquir Immune Defic Syndr*. 2012 Sep 1;61(1):73-7.
12. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30; 312(4): 410-25.
13. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet*. 2009 Sep 5;374(9692):796-806. Epub 2009 Aug 3.
14. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. *J Acquir Immune Defic Syndr*. 2009 Nov 1;52(3):350-6.
15. Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. *AIDS*. 2010 Jul 17;24(11):1697-707.
16. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. *Lancet Infect Dis*. 2012 Jan;12(1):27-35. Epub 2011 Oct 18.
17. National Institute of Allergy and Infectious Disease. [Accessed 2013 May] Available from: URL: http://health.nih.gov/.
18. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Accessed 2013 September] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm.
19. Patel DA, Snedecor SA, Tang WY, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. *Plos One*. 2014 Sept 4; 9(9).
20. Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve

subjects: the progress study, 48-week results. *HIV Clin Trials*. 2011 Sep-Oct;12(5):255-67.
21. Rockstroh JK, Teppler H, Zhao J, et al. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. *AIDS*. 2011 Jul 17;25(11):1365-9.
22. Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. *HIV Med*. 2012 Feb;13(2):127-31. Epub 2011 May 22.
23. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. *Lancet*. 2012 Jun 30;379(9835):2439-48.
24. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. *J Acquir Immune Defic Syndr*. 2013 May; 63(1):96-100.

Antivirals – HIV, CCR5 Co-Receptor Antagonists

1. Clinical Pharmacology. [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology.com/.
2. Drugs@FDA. [Accessed 2015 March] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Antiretroviral Treatment of Adult HIV Infection. 2010 Recommendations of the International AIDS Society – USA Panel. *JAMA*. 2010;304(3):321-333.
4. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. *J Infect Dis*. 2010 Mar 15;201(6):803-13.
5. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. *N Engl J Med*. 2008 Oct 2;359(14):1429-41.
6. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30; 312(4): 410-25.
7. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. *J Acquir Immune Defic Syndr*. 2010 Dec 15;55(5):558-64.
8. MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. *HIV Clin Trials*. 2011 Jan-Feb;12(1):24-36.

9. Mills A, Mildvan D, Podzamczer D, et al. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. *J Acquir Immune Defic Syndr*. 2013 Feb 1;62(2):164-70.
10. National Institute of Allergy and Infectious Disease. [Accessed 2013 May] Available from: URL: http://health.nih.gov/.
11. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Accessed 2013 May] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm.
12. Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. *HIV Clin Trials*. 2010 May-Jun;11(3):125-32.

Antivirals – HIV, Fusion Inhibitors

1. Clinical Pharmacology. [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology.com/.
2. Drugs@FDA. [Accessed 2015 March] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Antiretroviral Treatment of Adult HIV Infection. 2010 Recommendations of the International AIDS Society – USA Panel. *JAMA*. 2010;304(3):321-333.
4. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30; 312(4): 410-25.
5. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. *N Engl J Med.* 2003 May 29;348(22):2175-85. Epub 2003 Mar 13.
6. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. *N Engl J Med*. 2003 May 29;348(22):2186-95.
7. National Institute of Allergy and Infectious Disease. [Accessed 2013 May] Available from: URL: http://health.nih.gov/.
8. Nelson M, Arastéh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. *J Acquir Immune Defic Syndr*. 2005 Dec 1;40(4):404-12.
9. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Accessed 2013 May] Available from: URL: http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm.
10. Reynes J, Arastéh K, Clotet B, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. *AIDS Patient Care STDS*. 2007 Aug;21(8):533-43.
11. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in

treatment-experienced HIV-1-infected adults over 48 weeks. *J Acquir Immune Defic Syndr.* 2005 Dec 1;40(4):413-21.

Ophthalmic Agents

Antibiotics

1. Blephamide [package insert]. Irvine, CA: Allergan, Inc.; 2004.
2. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
3. Cortisporin ophthalmic ointment [package insert]. Bristol, TN: Monarch Pharma; 2003.
4. Cortisporin ophthalmic suspension [package insert]. Bristol, TN: Monarch Pharma; 2003.
5. FDA website. [Accessed 2015 March]. Available from: URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
6. Maxitrol [package insert]. Fort Worth, TX: Alcon Labs;2008.
7. Moxeza [package insert]. Fort Worth, TX: Alcon Labs; 2010.
8. Poly-Pred [package insert]. Irvine, CA: Allergan, Inc.; 2004.
9. Pred-G [package insert]. Irvine, CA: Allergan, Inc.; 2004.
10. TobraDex [package insert]. Fort Worth, TX: Alcon Labs; 2010.
11. Zylet [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2006.
12. Gigliotti F, Hendley J, Morgan J et al. Efficacy of topical antibiotic therapy in acute conjunctivitis in children. *Journal of Pediatrics* 1985; 104(4): 623-6.
13. Gwon A. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. *Br J Ophthamol* 1992; 76(12): 714-8.
14. Gwon A. Ofloxacin vs tobramycin for the treatment of external ocular infection. Oxfloxacin Study Group. *Arch Ophthalmol* 1992; 110 (9): 1234-7.
15. Lacey CF, Armstrong LL, Goldman MP, lance LL. Drug information handbook. Hudson, Ohio: Lexi-comp, Inc; 2001-2002.
16. Leibowitz HM, Hyndiuk RA, Smolin GR, et al. Tobramycin in external eye disease: a double-masked study vs. gentamicin. *Curr Eye Res* 1981; 1(5): 259-66. *Abstract.*
17. Morrow GL, Abbott RL. Conjunctivitis. *Amer Fam Physician* 1998; 57(4): 735-46.
18. Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective,three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther 2004;26: 1274-85.
19. Pharmacist Letter. May 2003. Zymar and Vigamox for Bacterial Conjunctivitis. Detailed-Document #190514.

20. Prajna NV, George C, Selvaraj S et al. Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture positive bacterial keratitis. *Cornea* 2001; 20(2): 175-8.
21. Thielen TL, Castle SS, Terry JE. Anterior Ocular Infections: An Overview of Pathophysiology and Treatment. *Ann Pharmocother* 2000; 34: 235-46.
22. White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/ tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008; 24(1):287-96.
23. Wolters Kluwer Health, Inc. (accessed 2012 May). Facts & Comparisons eAnswers, Available from: http://www.efactsweb.com.

Antihistamine/Mast Cell Stabilizers

1. Alocril [package insert], Irvine CA: Allergan Inc.; 2008.
2. Alomide [package insert],.Fort Worth, TX: Alcon Labs; 2002.
3. Bepreve [package insert]. Irvine, CA: ISTA Pharmaceuticals; 2012.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Cromolyn Sodium [monograph], eDrug Facts and Comparisons, Wolters Kluwer Health, Inc. 2003.
6. Elestat [package insert]. Irvine, CA: Allergan Inc.; 2011.
7. Emadine [package insert], Fort Worth, TX.: Alcon Labs; 2003.
8. Lastacaft [package insert], Irvine, CA: Allergan Inc.; 2010.
9. Optivar [package insert], Somerset, NJ: Meda Pharma; 2008.
10. Pataday [package insert], Fort Worth, TX.: Alcon Labs; 2010.
11. Patanol [package insert], Fort Worth, TX: Alcon Labs; 2003.
12. Pazeo [package insert]. Fort Worth, TX: Alcon Labs; 2015.
13. Zaditor [patient information], Novartis Pharmaceuticals Corporation. Available at: www.zaditor.com. Accessed 2009 May.
14. Abelson MB and Kaplan AP. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10mg and their combination in the human conjunctival allergen challenge model. *Clin Ther* 2002;24(3):445-56.
15. Abelson MB, Berdy GJ, Mondorf T, et al. Perimolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. *J Ocul Pharmacol Ther* 2002;18(5):475-88.
16. Ahluwalia P, Anderson DF, Wilson SJ, et al. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. *J Allergy Clin Immunol* 2001;108(3):449-54.
17. Berdy GJ, Spangler DL, Bensch G, et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution

in the conjunctival antigen challenge model. *Clin Ther* 2000;22(7):826-33.
18. Butrus S, Greiner JV, Discepola, et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. *Clin Ther* 2000;22(12):1462-72.
19. Caldwell DR, Verin P, Hartwich-Young R, et al. Efficacy and safety of lodoxamide 0.1% vs. cromolyn sodium 4% in patients with vernal keratoconjunctivitis. *Am J Ophthalmol* 1992;113:632-7.
20. D'Arienzo PA, Leonardi A, Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. *Clin Ther* 2002;24(3):409-16.
21. Facts and Comparisons. E-facts [cited 2012 March]. http://www.efactsweb.com.
22. Giede C, Metzenauer P, Petzold U, et al. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. *Curr Med Res Opin* 2000;16(3):153-63. (abstract)
23. Greiner JV, Minno G. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. *Clinical Therapeutics* 2003;25(7):1988-2005.
24. Katelaris CH, Ciprandi G, Missotten L, et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. *Clin Ther* 2002;24(10):1561-75.
25. Shulman DG, Amdahl L, Washington C, et al. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. *Clin Ther* 2003;25:1096-1106.
26. Shulman DG. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study. *Advances in Therapy* 2003;20(1):31-40. (abstract)
27. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. *Clin Ther* 2001;23(8):1272.80.
28. Tabbara KF, Al-Kharashi SA. Efficacy of nedocromil 2% versus fluoromethalone 0.1%: a randomized, double-masked trial comparing the effects on severe vernal keratoconjunctivitis. *Br J Ophthalmol* 1999;83(2):180-4.
29. Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. *Am J Ophthalmol* 2001;131(6):691-8.

30. Verin PH, Dicker ID, Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. *Clin Exp Allergy* 1999;29(4):529-36. (abstract)

Miotics

1. Alphagan P [prescribing information] Irvine, CA; Allergan Inc; 2010.
2. Azopt [prescribing information]. Fort Worth, TX; Alcon Labs; 2011.
3. Betoptic S [prescribing information]. Fort Worth, TX; Alcon Labs; 2007.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Combigan [prescribing information] Irvine, CA; Allergan Inc.; 2008.
6. Cosopt [prescribing information]. Whitehouse Station, NJ; Merck; 2009.
7. Lumigan [prescribing information]. Irvine, CA; Allergan Inc.; 2012.
8. Optipranolol [package insert] Tampa, FL; Bausch & Lomb Inc.; 2003.
9. Simbrinza [prescribing information]. Fort Worth, TX: Alcon Labs; 2013.
10. Timoptic XE [prescribing information]. Whitehouse Station, NJ; Merck; 2008.
11. Travatan Z [prescribing information]. Fort Worth, TX; Alcon Labs; 2011.
12. Trusopt [prescribing information]. Whitehouse Station, NJ; Merck; 2009.
13. Xalatan [prescribing information]. Woodstock, IL; Pfizer Inc.; 2012.
14. Zioptan [prescribing information]. Whitehouse Station, NJ; Merck; 2012.
15. Alward LM. Drug therapy: medical management of glaucoma. *N Engl J Med* 1998:339;1298-1307.
16. American Hospital Formulary Service Drug Information. 2002 Publication.
17. Aung T, Wong H, Yip C, et al. Comparison of the intraocular pressure lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma. *Ophthalmology* 2000; 107: 1178-1183.
18. Choudhri S, Wand M, Sheilds M. A comparison of dorzolamide-timolol combination versus the concomitant drugs. *American Journal of Ophthalmology* 2000*;* (130): 832-33.
19. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (Lumigan®) versus combined timolol and dorzolamide (Cosopt®) in patients with glaucoma or ocular hypertension. *Ophthalmology* 2003;110(12):2362-8.
20. Drug Facts and Comparisons 2012. Ophthalmic and Otic Agents/Agents for Glaucoma. Accessed at www.efactsweb.com [cited 2012 March].
21. Drug Information Handbook. 2002-2003 10th Anniversary Edition.
22. Electronic Orange Book 2012. Accessed at http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm 2013 Sept.

23. Higginbotham EJ, Olander KW, Kim EE. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. *Arch Ophthalmol.* 2010 Feb;128(2):165-72.
24. Honrubia FM, Larsson LI, Spiegel D. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. *Acta Ophthalmologica Scandinavica* 2002;80(6):635-41.
25. Hutzelmann J, Owens S, Sedden A. et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. *Br J Ophthalmol* 1998;82: 1249-1253.
26. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. *Journal of Glaucoma* 2002;11(2):119-26. Abstract only.
27. Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011 Apr;151(4):671-81. Epub 2011 Jan 22. Erratum in: *Am J Ophthalmol*. 2011 Jun;151(6):1108.
28. Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. *Journal of Ocular Pharmacology & Therapeutics* 2003;19(1):37-44.
29. Netland P, Landry T, Sullivan K et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *American Journal of Ophthalmology* 2001;(132): 472-484.
30. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. *American Journal of Ophthalmology* 2003;135(1):55-63.
31. O'Donoghue E. et al. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomized study. *Br J Ophthalmol 2000*; 84: 579-582.
32. Parrish R, Palmberg P and Sheu W. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week randomized, masked-evaluator, multicenter study. In Press; *American Journal of Ophthalmology* 2003;135(5):688-703.
33. Physicians Desk Reference. 2002 Publication.
34. Primary open-angle glaucoma guideline. American Academy of Ophthalmology. Febuary 2000.
35. Rolle T, Cipullo D, Vizzeri G et al. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results. *Acta Ophthalmologica Scandinavica Suppl* 2000; (232): 50-52.

36. Watson PG, Barnett MF, Parker V. et al. A 7 year prospective comparative study of three topical β blockers in the management of primary open angle glaucoma. *Br J Ophthalmol* 2001;85:962-968.

NSAIDs

1. Acular [package insert]. Irvine, CA: Allergan, Inc.; 2012.
2. Acuvail [package insert]. Irvine, CA: Allergan, Inc.; 2009.
3. Bromday [package insert]. Irvine, CA: Ista Pharmaceuticals; 2011.
4. Clinical Pharmacology. [Accessed 2015 March] http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Ilevro [package insert]. Fort Worth, TX: Alcon Labs; 2012.
6. Nevanac [package insert]. Fort Worth, TX: Alcon; 2011.
7. Ocufen [package insert]. Irvine, CA: Allergan, Inc.; 2012.
8. Voltaren Ophthalmic [package insert]. East Hanover, NJ: Novartis Pharma; 2009.
9. Donnenfeld ED, Holland EJ, Durrie DS, et al. Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial would healing and pain after photorefractive keratectomy. *Adv Ther* 2007 Jul-Aug;24(4):852-62.
10. Duong HV, Westfield KC, Chalkley TH. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. *J Cataract Refract Surg* 2007 Nov;33(11):1925-9.
11. Durrie DS, Kennard MG, Boghossian AJ. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). *Adv Ther* 2007 Nov-Dec;24(6):1278-85.
12. Electronic Orange Book. [cited 2009 September] http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm.
13. Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. *Ophthalmology* 1998 Sep;105(9):1775-9.
14. Kastrup EK, Ed. Drug Facts and Comparisons (EFacts). Facts & Comparisons. St. Louis. 2009.
15. Narvaez J, Krall P, Tooma TS. Prospective, randomized trial of diclofenac and ketorolac after refractive surgery. *J Refract Surg* 2004 Jan-Feb;20(1):76-8.
16. Sandoval HP, De Castro LE, Vroman DT, et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. *J Ocul Pharmacol Ther* 2006 Aug;22(4):251-7.
17. Tauber J, Raizman MB, Ostrov CS. et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. *J Ocul Pharmacol Ther* 1998 Apr;14(2):137-45.

Otic Agents

Antibiotics

1. Cetraxal [package insert]. Ridgeland, MS: WraSer Pharma; 2009.
2. Cipro HC [package insert]. Fort Worth, TX: Alcon, Inc; 2002.
3. Ciprodex [package insert]. Fort Worth, TX: Alcon, Inc; 2003.
4. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Floxin Otic [package insert]. Montvale, NJ: Daiichi Pharma; 2005.
6. Agros AS, Garner ET, Wright JW et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. *Clin Ther* 1998; 20(4): 744-59.
7. Clinical practice guideline: Acute otitis externa. *Otolaryngology-Head and Neck Surgery* 2006; 134: 4-23.
8. Diagnosis and Management of Acute Otitis Media. *Pediatrics* 2004; 113(5): 1451-1465.
9. Drug Facts and Comparison. [Accessed 2012 May]. Available from: URL: www.efactsweb.com.
10. Drug Information Online. [Accessed 2010 Dec]. Available from: URL: http://www.drugs.com/.
11. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. Hudson, Ohio: Lexi-Comp, Inc; 2001-2002.
12. Miro N. Controlled multicenter study on chronic suppurative otitis media treated with topical applications of ciprofloxacin 0.2% solution in single-dose containers or combination of polymyxin B, neomycin, and hydrocortisone suspension. *Otolarynogol Head Neck Surg* 2000; 123(5): 617-23.
13. Monthly Prescribing Reference. December 2002. Ear Disorders. Pages 119.
14. Rx List [Accessed 2009 May]. Available from: URL: http://www.rxlist.com.
15. Schwartz RH. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. *Current Medical Research and Opinion* 2006; 22(9): 1725-1736.
16. Tong MC, Woo JK, &van Hasselt CA. A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. *J Laryngol Otol* 1996; 110(4): 309-14.
17. Tutkun A, Ozagar A, Koc A, et al. Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin. *Arch Otolaryngol Head Neck Surg* 1995; 121(12): 1414-6.

Respiratory Agents

Antihistamines – Second Generation

1. Allegra [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2007.
2. Clarinex [package insert]. Kenilworth, NJ: Schering Corporation; 2007.
3. Gold Standard, Inc (Accessed 2015 March). Clinical Pharmacology. URL:http://clinicalpharmacology.com.
4. Xyzal [package insert]. Smyrna, GA: UCB Inc.; 2010.
5. Zyrtec [package insert]. New York, NY: Pfizer; 2006.
6. Day J, Briscoe M, Widlitz M. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit. *J Allergy Clin Immunol* 1998;101:638-645.
7. Dubuske and the desloratadine study group. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks. *J Allergy Clin Immunol* 2001;107:S159.
8. Guerra L, Vincenzi C, Marchesi A, et al. Loratadine and cetirizine in the treatment of chronic urticaria. *J Eur Acad of Dermatol and Venereol* 1994;3:148-152.
9. Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180mg, exhibits equivalent efficacy to cetirizine, 10mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2003;91:354-361.
10. Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg o.d. and fexofenadine 120mg o.d. in reducing symptoms of seasonal allergic rhinitis. *Int Arch Allergy Immunol* 2001;125:73-79.
11. Howarth P, Stern M, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. *J Allergy Clin Immunol* 1999;104:927-33.
12. Kaiser H, Rooklin A, Spangler D, Capano D. Efficacy of loratadine compared with fexofenadine or placebo for the treatment of seasonal allergic rhinitis. *Clin Drug Invest* 2001;21(8):571-578.
13. Orange book. Accessed www.fda.gov/cder/ob/default.htm 2012 Dec: patent expiration dates.
14. Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. *Ann Allergy Asthma Immunol*. 2008 Sep;101(3):287-94.
15. Peripherally selective antihistamines. In: Hebel SK, ed. Drug Facts and Comparisons, St. Louis: Facts and Comparisons, Inc., 2001.
16. Prenner B, Capano D, Harris A. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: A double-blind comparison with crossover treatment of nonresponders. *Clin Thers* 2000;22(6):760-769.

17. Purohit A, Duvernelle C, Melac M, et al. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. *Ann Allergy Asthma Immunol* 2001;86(4):387-392.
18. Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. *Ann Allergy Asthma Immunol* 2004; 92: 635-640.
19. Salmun LM, Gates D, Scharf M, et al. Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. *Clin Ther* 2000; 22(5):573-82.
20. Simons FE, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: A randomized, double-blind, placebo-controlled study. *J Allergy Clin Immunol* 2003;111:1244-1248.
21. Van Cauwenberge P, Juniper E, and the Star Study Investigating Group. Comparison of the efficacy, safety, and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. *Clin Expl Allergy* 2000;30:891-899.
22. Wilken JA, Kane RL, Ellis AK, et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. *Ann Allergy Asthma Immunol* 2003;91:375-385.
23. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. *Clin Exp Allergy* 2002;32:1504-9.

Beta-adrenergic Agents – Inhaled

1. Arcapta [package insert].East Hanover, NJ: Novartis Pharma; 2012.
2. Brovana [package insert]. Marlborough, MA: Sepracor Inc.; 2014.
3. Foradil [package insert]. Kenilworth, NJ: Schering Corporation; 2012.
4. Gold Standard, Inc (Accessed 2015 March). Clinical Pharmacology. URL:http://clinicalpharmacology.com.
5. Perforomist [package insert]. Napa, CA; Dey; 2012.
6. Proair HFA [package insert]. Horsham, PA: Teva Specialty Pharmaceuticals, LLC; 2012.
7. Serevent [package insert]. Research Triangle Park, NC: GlaxoSmithKline, Inc.; 2011.
8. Striverdi Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2014.
9. Xopenex HFA [package insert]. Marlborough, MA: Sepracor; 2012.
10. Xopenex Inhalation Solution [package insert]. Marlborough, MA: Sepracor; 2012.
11. Anderson PO (ed.), Knoben JE (ed), Troutman WG (ed). Handbook of Clinical Drug Data, ninth edition. Appleton & Lange. Stanford (CT); 1999.

12. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996;153(3):967-75.
13. Bensch G, Lapidus RJ, Lavine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. *Ann Allergy Asthma Immunol* 2001;86:19-27.
14. Berkowitz R, Schwartz E, Bukstein D, et al. Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate. *Pediatrics* 1986;77(2):173-8.
15. Brown RW, O'Brien CD, Martin UJ, et al. Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: arandomized controlled trial. J Allergy Clin Immunol 2012;130(2):362-7.
16. Campbell LM, Anderson TJ, Paraschchak MR, et al. A comparison of the efficacy of long-acting β_2-agonists: eformoterol via Turbohaler® and salmeterol via pressurized metered dose inhaler or Accuhaler®, in mild to moderate asthmatics. *Respir Med* 1999;93:236-44.
17. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. *J Pediatr* 2003;143:731-6.
18. D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. *JAMA* 1994;271:1412-16.
19. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. *Chest* 2001;119(5):1347-1356.
20. Donohue JF. The expanding role of long-acting beta-agonists. *Chest* 2000;118(2):283-285.
21. Drug Facts and Comparisons 4.0. Facts and Comparisons. St. Louis (MO): 2012.
22. Ferguson GT. Update on pharmacologic therapy for chronic obstructive pulmonary disease. *Clin Chest Med* 2000;21(4):723-738.
23. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2-4 COPD: results from two replicate 48 week studies. *International Journal of COPD* 2014 Jun 16;9:629-45.
24. Horiuchi T, Castro M. The pathobiologic implications for treatment: old and new strategies in the treatment of chronic asthma. *Clin Chest Med* 2000;21(2):381-395.
25. Johnson M and Rennard S. Alternative mechanisms for long-acting beta$_2$-adrenergic agonists in COPD. *Chest* 2001;120(1):258-270.
26. Lacy CF, et al (eds.). Drug Information Handbook. Lexi-Comp, Inc. Hudson (OH): 2012.

27. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975-85. Epub 2010 Mar 2.
28. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. *Chest* 2003;124:70-74.
29. McEnvoy GK (ed). AHFS Drug Information 2002. American Society of Health-System Pharmacists, Inc. Bethesda (MD): 2002.
30. Milgrom H, Skoner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. *J Allergy Clin Immunol* 2001;108(6):938-45.
31. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma- Update on selected topics 2002. Bethesda, MD: National Institutes of Health;2002. Publication NIH 02-5075. Available at: www.nhlbi.nih.gov.
32. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. *J Allergy Clin Immunol* 1998;102(6 Pt1):943-52.
33. Orange book. Accessed www.fda.gov/cder/ob/default.htm on Dec 2009: patent expiration dates.
34. Orgel HA, Kemp JP, Tinkleman DG, et al. Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. *J Allergy Clin Immunol* 1985;75(1 Pt1):55-62.
35. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to moderate asthma. *N Engl J Med* 1992;327:1420-5.
36. Sears MR. Deleterious effects of inhaled beta-agonists: short-acting and long-acting agents differ. *Chest* 2001;119(5):1297-1299.
37. Tinkelman DG, Brandon ML, Grieco M, et al. Comparison of safety and efficacy of inhaled pirbuterol with metaproterenol. *Ann Allergy* 1990;64(2 Pt2):202-6. (Abstract)
38. Van Noord JA. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. *Eur Respir J* 1996;9(8):1684-1688.
39. Vervloet D, Ekstrom T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. *Respir Med* 1998;92:836-842.
40. Wolfe JD, Shapiro GG, Ratner PH. Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma. *Pediatrics* 1991;88(2):312-9.
41. Zehner WJ Jr., Scott JM, Iannolo PM, et al. Terbutaline vs. albuterol for out-of-hospital respiratory distress: randomized double-blind trial. *Acad Emerg Med* 1995;2(8):686-91.

Beta-adrenergic Combinations

1. Advair Diskus [package insert]. Research Triangle Park, NC: GSK; 2010.
2. Advair HFA [package insert]. Research Triangle Park, NC: GSK; 2012.
3. Breo Ellipta [package insert]. Research Triangle Park, NC: GSK; 2013.
4. Clinical Pharmacology, Gold Standard Multimedia Inc. (accessed 2015 March). URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
5. Dulera [package insert]. Whitehouse Station, NJ: Schering/Merck; 2013.
6. Symbicort [package insert]. Wilmington, DE: AstraZeneca; 2010.
7. Brown RW, O'Brien CD, Martin UJ, et al. Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: arandomized controlled trial. J Allergy Clin Immunol 2012;130(2):362-7.
8. Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. *Respir Med*. 2003;97:323-30.
9. Hampel FC, Martin P, Mezzanotte WS. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. *J Asthma.* 2008 May;45(4):265-72.
10. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The efficacy and safety of fluticasone propionate (250ug)/salmeterol (50 ug) combined in the diskus inhaler for the treatment of COPD. *Chest*. 2003;124(3):834-43.
11. Kaiser, H., et al. Onset of Effect of Budesonide and Formoterol Administered Via One Pressurized Metered-Dose Inhaler in Adults and Adolescents with Asthma Previously Treated with Inhaled Corticosteroids. *Annals of Allergy, Asthma and Immunology*. 2008; 101(3):295-303.
12. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomized trial of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg) on lung function in COPD. *Respir Med.* 2013 Apr;107(4):560-9.
13. Koenig SM, Ostrom N, Pearlman D, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". *J Asthma.* 2008 Oct;45(8): 681-7.
14. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975-85. Epub 2010 Mar 2.
15. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. *J Allergy Clin Immunol*. 2001;107(5):783-9.
16. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma- Update on selected topics 2002.

Bethesda, MD: National Institutes of Health;2002. Publication NIH 02-5075. Available at: www.nhlbi.nih.gov.
17. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. *J Allergy Clin Immunol*. 2000;106(6):1088-95.
18. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in adults and adolescents with moderate to severe asthma. *Drugs*. 2006;66:2235-54.
19. Orange Book. Accessed www.fda.gov/cder/ob/default.htm 2013 Sept: patent expiration dates.
20. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med*. 2008 Jan 1;177(1):19-26.

COPD Agents

1. Anoro Ellipta [package insert]. Research Triangle Park, NC: GSK; 2013.
2. Atrovent HFA [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012.
3. Combivent Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012.
4. Daliresp [package insert]. St. Louis, MO: Forest Pharmaceuticals Inc.; 2013.
5. DuoNeb [package insert]. Napa, CA: Dey; 2012.
6. Gold Standard, Inc (Accessed 2014 Feb). Clinical Pharmacology. URL:http://clinicalpharmacology.com.
7. Spiriva [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2011.
8. Spiriva Respimat [package insert]. Ridgefield, CT: Boehringer Ingelheim; September 2014.
9. Tudorza [package insert].Louis, MO: Almirall; 2012.
10. Brusasco V. Hodder R. Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. *Thorax* 2003;58(5):399-404.
11. Casaburi R. Mahler DA. Jones PW. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. *Eur Respir Jl* 2002;19(2):217-24.
12. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. *Chest.* 1994;105(5):1411-9.
13. Donohue JF. van Noord JA. Bateman ED. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in

COPD patients treated with tiotropium or salmeterol. *Chest*. 2002;122(1):47-55.
14. Dorinsky PM. Reisner C. Ferguson GT. et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. *Chest.* 1999;115(4):966-71.
15. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 mcg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. *Chest* 2012 Mar;141(3):745-52.
16. Karner C, Chong J, Poole P, et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2014 Jul 21;7:CD009285.
17. National Institute of Health Publication. Global Initiative for Chronic Obstructive Lung Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary, 2008 update. [cited 2009 May]. Available at http://www.goldcopd.com.
18. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *N Engl J Med*. 2010 Oct 28;363(18):1715-26.
19. Sin DD. McAlister FA. Man SFP, et al. contemporary management of chronic obstructive pulmonary disease. *JAMA* 2003;290:2301-12.
20. Sutherland ER. Cherniack RM. et al. Management of chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:2689-97.
21. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT TRIAL). *N Engl J Med.* 2008 Oct 9;359(15):1543-54. Epub 2008 Oct 5.
22. The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. *Chest* 1997;112(6):1514-21.
23. van Noord JA. Bantje TA. Eland ME et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. *Thorax* 2000;55(4):289-94.
24. Vincken W. van Noord JA. Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. *Eur Respir J* 2002;19(2)209-16.
25. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med*. 2008 Jan 1;177(1):19-26.
26. Zuwallack R, De Salvo MC, Kaelin T, et al. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. Respir Med 2010;104(8):1179-88.

Glucocorticoid Agents – Inhaled

1. Aerospan HFA [package insert]. St. Louis, MO: Forest Labs; 2013.

2. Alvesco [package insert]. Florham Park, NJ: Nycomed US Inc.; 2012.
3. Asmanex Twisthaler [package insert]. Kenilworth, NJ: Schering Corporation; 2010.
4. Flovent HFA [package insert]. Research Triangle Park, NC: GSK; 2013.
5. Gold Standard, Inc (accessed 2015 March). Clinical Pharmacology. URL:http://clinicalpharmacology.com.
6. Pulmicort Flexhaler [package insert]. Wilmington, DE: AstraZeneca; 2010.
7. Pulmicort Respules [package insert]. Wilmington, DE: AstraZeneca; 2010.
8. QVAR [package insert]. Horsham, PA: Teva Specialty Pharmaceuticals, LLC; 2012.
9. Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. *Eur Respir J* 1995; 8:579-86.
10. Baraniu J, Murray JJ, Nathan RA, Berger WE, Johnson M, Edwards LD, et al. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. *Chest* 1999; 116:625-32.
11. Berkowitz R, Rachelefsky G, Harris AG, Chen R. A comparison of triamcinolone acetonide MDI with a built-in tube extender and beclomethasone dipropionate MDI in adult asthmatics. *Chest* 1998; 114:757-65.
12. Boushey HA, Soarkness CA, King TS, Sullivan SD, Fahy JV, et al. Daily versus as-needed corticosteroids for mild persistent asthma. *N Engl J Med* 2005 Apr 14; 352(15): 1519-28.
13. Bronsky E, Korenblat P, Harris AG, Chen R. Comparative clinical study of inhaled beclomethasone dipropionate and triamcinolone acetonide in persistent asthma. *Ann Allergy Asthma Immunol* 1998; 80:295-302.
14. Brown RW, O'Brien CD, Martin UJ, et al. Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: arandomized controlled trial. J Allergy Clin Immunol 2012;130(2):362-7.
15. Condemi JJ, Chervinsky P, Goldstein MF, Ford LB, Berger WE, Ayars GH, et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. *J Allergy Clin Immunol* 1997; 100:467-74.
16. FDA Orange Book (accessed 2009 Dec). Available at: http://www.fda.gov/cder/orange/default.htm.
17. Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, and Cohen RM. Longterm safety and efficacy of a chlorofluorocarbon-free beclomethasone diproprionate extrafine aerosol. *Ann Allergy Asthma Immunol* 2001; 86:557-65.
18. Gelman CR, Moore MB, Hutchinson TA, editors: DRUGDEX® System. MICROMEDEX, Inc., Englewood, (CO) (Online Edition [2009]).

19. Leblanc P, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma. *Allergy* 1994; 49:380-85.
20. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *N Engl J Med*. 2010 Mar 18;362(11):975-85. Epub 2010 Mar 2.
21. Lundback B, Alexander M, Day J, Hebert J, Holzer R, Van Uffelen R, et al. Evaluation of fluticasone propionate (500 μg day^{-1}) administered either as dry powder via Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day^{-1}) administered by pressurized inhaler. *Respir Med* 1993; 87:609-20.
22. Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. *J Asthma*. 2007 Sep;44(7):555-63.
23. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2011 Feb 19;377(9766):650-7. Epub 2011 Feb 14.
24. McEvoy GK, Litvak K, Welsh OH, Snow EK, Dewey DR, editors. AHFS Drug Info. Bethesda (MD): American Society of Health-System Pharmacists; 1999.
25. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma- Update on selected topics 2002. Bethesda, MD: National Institutes of Health; 2002. Publication NIH 02-5075. Available at: www.nhlbi.nih.gov.
26. Newhouse M, Knight A, Wang S, Newman K, AER-MD-04 Study Group. Comparison of efficacy and safety between flunisolide/AeroChamber and budesonide/turbuhaler in patients with moderate asthma. *Ann Allergy Asthma Immunol* 2000; 84:313-19.
27. Rodrigo G, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. *Chest* 2003; 123:1908-1915.
28. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. *Pulm Pharmacol Ther.* 2007;20(5):562-70. Epub 2006 Jul 11.
29. Willey RF, Godden DJ, Carmichael J, Preston P, Frame MH, Crompton GK. Twice daily inhalation of corticosteroid budesonide, in the treatment of chronic asthma. *Astra Clinical Research Unit.* Edinburgh, Scotland.

Hereditary Angioedema Agents – Class Under Review

Leukotriene Receptor Modifiers and Inhibitors

1. Accolate [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2013.

2. Singulair [package insert].Whitehouse Station, NJ: Merck & Co., Inc.; 2013.
3. Zyflo [package insert]. Lexington, MA: Critical Therapeutics; 2012.
4. Zyflo CR [package insert]. Lexington, MA: Critical Therapeutics; 2011.
5. Asthma in Children Fact Sheet. American Lung Association http://www.lung.org/ [cited 2009 May].
6. Average Wholesale Price. FirstDataBank, update Apr 2007.
7. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double-blind, randomized, comparative trial. BMJ 2003;327:891-895.
8. Electronic Orange book. Accessed at www.fda.gov/cder/ob/default.htm 2012 Dec: patent expiration dates.
9. Grossman J, Smith LJ, Wilson AM, et al. Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. *Ann Allergy Asthma Immunol* 82(4):361-9, 1999 Apr.
10. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. *JAMA*. 275(12):931-6, 1996 Mar 27.
11. Kemp JP, Korenblat PE, Scherger JE, et al. Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. *J Fam Prac* 48(6):425-32, 1999 Jun.
12. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics* 108(3):E48, 2001 Sep.
13. Koenig SM, Ostrom N, Pearlman D, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". *J Asthma.* 2008 Oct;45(8): 681-7.
14. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *New Eng J Med* 339(3):147-52, 1998 Jul 16.
15. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *N Engl J* Med. 2010 Mar 18;362(11):975-85. Epub 2010 Mar 2.
16. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. *J Allergy Clin Immunol* 98(5 Pt 1):859-71, 1996 Nov.
17. NAEPP Expert panel report. Guideline for diagnosis, management of asthma – update on selected topics 2007. Available at: http://www.nhlbi.nih.gov.

18. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *J Allergy Clin Immunol* 102(6 Pt 1):935-42, 1998 Dec.
19. Nayak AS, Phillip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. *Ann Allergy Asthma Immunol* 88(6):592-600, 2002 Jun.
20. Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. *Ann Allergy Asthma Immunol*. 2008 Sep;101(3):287-94.
21. Robinson DS, Campbell D, Barnes PJ, et al. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. *Lancet* 357(9273):2007-11, 2001 Jun 23.
22. van Adelsberg J, Phillip G, LaForce CF, et al.. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 90(2):214-22, 2003 Feb.

Nasal Preparations

1. Astelin [package insert]. Somerset, NJ: MedPointe Healthcare Inc; 2012.
2. Astepro [package insert]. Somerset, NJ: Meda Pharmaceuticals; 2010.
3. Atrovent [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2011.
4. Beconase AQ [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
5. Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals; 2012.
6. Flonase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
7. Gold Standard, Inc (accessed 2015 March). Clinical Pharmacology. URL:http://clinicalpharmacology.com.
8. Nasacort AQ [package insert]. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals, Inc; 2008.
9. Nasalide [package insert]. San Diego, CA: Elan Pharmaceuticals; 2000.
10. Nasonex [package insert]. Kenilworth, NJ: Schering; 2011.
11. Omnaris [package insert]. Florham Park, NJ: Nycomed Us Inc; 2013.
12. Patanase [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2010.
13. QNASL [package insert]. Horsham, PA: Teva Respiratory LLC; 2012.
14. Rhinocort Aqua [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2010.
15. Veramyst [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.

16. Zetonna [package insert]. Marlborough, MA: Sunovion Pharma Inc.; 2012.
17. Approved Drug Products with Therapeutic Equivalence Evaluations: Electronic Orange Book. [cited 2009 Dec]. Available from: http://www.fda.gov/cder/ob/default.htm.
18. Average Wholesale Price. FirstDataBank, update Aug 2002.
19. Bende M, Carrillo T, Vona I, Castel-Branco M, and Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. *Ann Allergy Asthma Immunol* 2002;88:617-623.
20. Berger W, Fineman S, and Lieberman P. Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 1999;82:535-541.
21. Berger WE, White MV, et al. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. *Ann Allergy Asthma Immunol* 2003;91:205-211.
22. Bernstein JA, Prenner B, Ferguson BJ, et al. Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. *Am J Rhinol Allergy.* 2009 Sep-Oct;23(5):512-7.
23. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelatine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129(5):1282-9.
24. Day J, and Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. *J Allergy Clin Immunol* 1998;102:902-8.
25. Grubbe R, Adelglass JM, Casasle TE, Cohen R, Jacobson KW, Klaustermeyer WB, et al. Intranasal therapy with once-daily triamcinolone acetonide aerosol versus twice daily beclomethasone diproprionate aqueous spray in patients with perennial allergic rhinitis. *Curr Ther Res* 1996;11:825-38.
26. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105(2):168-73.
27. Langrick AF. Comparison of flunisolide and beclomethasone dipropionate in seasonal allergic rhinitis. *Curr Med Res Opin* 1984;9:5:290-295.
28. Mandle M, Nolop K, and Lutsky BN. Comparison of once daily Mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays in the treatment of perennial rhinitis. *Ann Allergy Asthma Immunol* 1997;79:370-45.
29. Pearlmann DS, Grossman J, Meltzer EO. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients

with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2003;91:258-262.
30. Pipkorn U, Geterud A. A comparative trial testing budesonide and flunisolide nasal sprays in patients with seasonal allergic rhinitis. *Annals of Allergy* 1984;52:183-186.
31. Potter PC, Niekerk CHV, and Schoemann HS. Effects of triamcinolone on quality of life in patients with persistent allergic rhinitis. *Ann Allergy Asthma Immunol* 2003;91:368-374.
32. Ratner PH, Hame; F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100(1):74-81.
33. Sipila P, Sorri M, Ojala K, Palva A. Comparative Trial of Flunisolide and Beclomethasone Dipropionate Nasal sprays in patients with seasonal allergic rhinitis. *Allergy* 1983; 38:303-307.
34. Small P, Houle PA, Day JH, Briscoe M, Gold M, Brodarec I, et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis*. J Allergy Clin Immunol* 1997;100:592-5.
35. Stern M, Wade A, Ridout S, et al. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. *Ann Allergy Asthma Immunol* 1998;81:354-358.

Self-Injectable Epinephrines

1. Adrenaclick [package insert]. Atlanta, GA: Sciele Pharma, Inc; 2011.
2. Auvi-Q [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2012.
3. Epipen and Epipen Jr [package insert]. Columbia, MD: Meridian Medical Technologies for Mylan Specialty LP; 2012.
4. Twinject [package insert]. Atlanta, GA: Shionogi Pharma, Inc; 2010.
5. Simons KJ and Simons FE. Epinephrine and its use in anaphylaxis: current issues. *Curr Opin in Allergy and Clin Immunol.* 2010;10:354-361.
6. Guerlain S, Hugine A, Wang L. A comparison of 4 epinephrine autoinjector delivery systems: usability and patient preference. *Ann Allergy Asthma Immunol.* 2010;104:172-7.
7. Sheikh A, Simons FE, Barbor V, Worth A. Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community. *Cochrane Database Syst Rev*. 2012;8:CD008935.
8. Edwards ES, Gunn R, Simons ER et al. Bioavailability of epinephrine from Auvi-Q compared with Epipen. *Ann Allergy Asthma Immunol*. 2013 Aug;111(2):132-7.

Topical Agents

Acne Agents

1. Acanya [package insert]. Aliso Viejo, CA: Valeant Pharma; 2010.
2. Aczone [package insert]. Irvine, CA: Allergan, Inc; 2008.
3. Atralin [package insert]. Fort Worth, TX: Coria Labs; 2007.
4. Azelex [package insert]. Irvine, CA: Allergan, Inc.; 2003.
5. Clinical Pharmacology [Accessed 2015 March] Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
6. Differin [package insert]. San Antonio, TX: Galderma Laboratories, L.P; 2003.
7. Epiduo [package insert]. Fort Worth, TX: Galderma Labs; 2008.
8. Retin-A Micro [package insert]. Skillman, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2002.
9. Ziana [package insert]. Scottsdale, AZ: Medicis, The Dermatology Company; 2006.
10. do Nasimento LV, Guedes AC, Magalhaes GM, et al. Single-blind and comparative study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% gel (QD) in the treatment of acne vulgaris for 11 weeks [Abstract]. *J Dermatolog Treat* 2003; 14(3): 166-71.
11. Drug Information Online [Accessed 2010 September] Available from: URL: http://www.drugs.com/.
12. Eichenfield LF, Jarrat M, Schlessinger J, et al. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controllled, multicenter, randomized double-blind, clinical studies [Abstract]. *Journal of Drugs in Dermatology* 2010 Jun; 9(6): 639-46.
13. Expert Committee Recommendations for Acne Management. *Pediatrics 2006; 118: 1188-1199.*
14. Facts & Comparisons® eAnswers [Accessed 2010 August]. Available from: URL: http://online.factsandcomparisons.com.
15. *Family Practice Notebook*. [Accessed 2010 September] http://fpnotebook.com.
16. Lacey CF, Armstrong LL, Goldman MP, Lance LL. *Drug Information Handbook* 2001-2002. Hudson, Ohio: Lexi-Comp Inc.
17. Leyden JJ, Berger RS, Dunlap FE, et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatment of acne [Abstract]. *Am J Clin Dermatol* 2001; 2(1): 33-9.
18. Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product [Abstract]. *J Cutan Med and Surg* 2001; 5(1): 37-42.
19. Lucky A, Jorizzo JL, Rodriguez D et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris [Abstract]. *Cutis* 2001; 68(4 Suppl): 34-40.

20. Lucky AW, Cullen SI, Funicella T et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. *J Am Acad Dermatol* 1998; 38: S24-30.
21. Micromedex®1.0 (Healthcare Series), (electronic version). Thomson Reuters (Healthcare) Inc., Greenwood Village, Colorado, USA. Available at: http://www.thomsonhc.com [Accessed 2010 September].
22. Nyirady J, Grossman RM, Nighland M et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. *J Dermatolog Treat* 2001; 12(3): 149-57.
23. Pariser D, Colon LE, Johnson LA et al. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris [Abstract]. *Journal of Drugs in Dermatology* 2008; 7(6 Suppl): s18-23.
24. *Physicians' Desk Reference*, fifty-eighth edition. Thompson PDR. Montvale (NJ): 2004.
25. Rx List. [Accessed 2010 September] http://www.rxlist.com.
26. Spellman MC and Pincus SH. Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. *Clin Ther* 1998; 20(4).
27. Thiboutot D, Arsonnaud S, Soto P, et al. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris [Abstract]. *Journal of Drugs in Dermatology* 2008; 7(6 Suppl): s3-10.
28. Webster GF, Guenther L, Poulin YP et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris [Abstract]. *Cutis* 2002; 69(2 Suppl): 4-11.
29. Webster GF. Acne vulgaris. *BMJ* 2002; 325: 475-78.
30. Wells BG, Dipiro JT, Schwinghammer TL, Hamilton CW, eds. *Pharmacotherapy Handbook, second edition*. Samford, Connecticut: Appleton & Lang; 2000.
31. Wolf JE Jr., Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. *J Am Acad Dermatol* 2003; 49(3 Suppl): S211-7.

Androgenic Agents

1. Androderm [package insert]. Parsippany, NJ: Watson Pharma, Inc.; 2013.
2. AndroGel 1% [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
3. AndroGel 1.62% [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
4. Axiron [package insert]. Indianapolis, IN:Lilly USA, LLC; 2011.
5. Fortesta [package insert]. Malvern, PA: Endo Pharmaceuticals, Inc.; 2012.

6. Testim [package insert]. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2009.
7. Testopel [package insert]. Durham, NC: Slate Pharmaceuticals; 2012.
8. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999 Oct;84(10):3469-78.
9. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53.
10. Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011 Jul;8(7):2079-89.
11. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003 Jan;91(1):69-74.
12. Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl. 2012 Jul-Aug;33(4):601-7.
13. Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf). 2011 Dec;75(6):836-43.
14. Fennell C, Sartorius G, Ly LP, et al. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf). 2010 Jul;73(1):102-9. doi: 10.1111/j.1365-2265.2009.03744.x. Epub 2009 Nov 5.

Antifungals

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Ertaczo [package insert]. Los Angeles, CA: Ortho-McNeil Pharmaceuticals, Inc; 2014.
3. Lotrisone [package insert]. Kenilworth, NJ: Schering Corporation; 2008.
4. Luzu [package insert]. Bridgewater, NJ: Medicis; 2013.
5. Mentax [package insert]. Sugar Land, TX: Mylan Bertek Pharmaceuticals, Inc; 2002.
6. Naftin [package insert]. Greensboro, NC: Merz Pharmaceuticals; 2012.
7. Penlac [package insert]. Bridgewater, NJ: Dermik Laboratories; 2004.
8. Xolegel [package insert]. Princeton, NJ: Barrier Therapeutics, Inc; 2012.
9. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. *Int J Dermatol* 1996;35(8):591-3.

10. Almoar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses (Abstract). *Arzneimittel-Forschung* 1992:42:767-773.
11. Cullen SI, Rex IH, Thorne EG. A comparison of a new antifungal agent, 1 percent econazole nitrate (Spectazole) cream versus 1 percent clotrimazole cream in the treatment of intertriginous candidosis. *Curr Ther Res* 1984;35(4):606-9.
12. Diehl KB. Topical antifungal agents: An update. *Am Fam Physician* 1996;54(5):1687-1692.
13. Drake LA, Dinehart SM, Farmer ER et al. American Academy of Dermatology- Guidelines of care for superficial mycotic infections of the skin: Tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. *J Am Acad Dermatol* 1996;34(2):282-6.
14. Electronic Orange Book: http://www.fda.gov/cder/ob/default.htm.
15. Garber G. An overview of fungal infections. *Drugs* 2001;61(Suppl 1): 1-12.
16. Gupta AK, Adam P, Dlova N et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. *Pediatr Dermatol* 2001;18(5):433-8.
17. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses: A North American perspective. *Drugs* 1998;55(5): 645-74.
18. Lassus A, Forsstrom S. A double-blind parallel study comparing sulconazole with econazole in the treatment of dermatophytes. *Mykosen* 1984;27(12):592-8.
19. Meis J, Verweij PE. Current management of fungal infections. *Drugs* 2001;61(Suppl 1): 13-25.
20. Millikan LE, Galen WK, Gewirtzman GB et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. *J Am Acad Dermatol* 1988;18:52-6.
21. Schopf R, Hettler O, Brautigam M et al. Efficacy and tolerability of terbinafine 1% topical solution for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multi-centre, 8-week clinical trial. *Mycoses* 1999;45(5-6):415-20.
22. Smith EB, Wiss K, Hanifin JM et al. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. *J Am Acad Dermatol* 1990;22(6):1116-7.
23. Suschka S, Fladung B, Merk HF. Clinical comparison of the efficacy and tolerability of once daily Canesen® with twice daily Nizoral® (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis. *Mycoses* 2002;45(3-4):91-6.
24. Susilo R, Korting HC, Strauss UP. Dermatomycoses of the glabrous skin: A double-blind, randomised, comparative trial of sertaconazole 2%

cream once daily versus vehicle (Abstract). *Clinical Drug Investigation* 2003;23(6):387-394.
25. Tanenbaum L, Anderson C, Rosenberg MJ et al. Sulconazole nitrate 1% cream: A comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. *Cutis* 1982;30:105-7.
26. Tanenbaum L, Anderson C, Rosenberg MJ, Akers W. 1% sulconazole cream v. 2% miconazole cream in the treatment of tinea versicolor. *Arch Dermatol* 1984;120:216-9.
27. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. *Am Fam Physician* 2002;65:2095-102.

Corticosteroids

1. Clinical Pharmacology [accessed 2015 March] http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Facts and Comparisons Online. Wolters Kluwer Health [accessed 2012 April]. http://online.factsandcomparisons.com.
3. Jacobson C, Cornell RC, Savin RC. A comparison of Clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. *Cutis.* 1986 Mar;37(3):213-4, 216, 218-20.
4. James M. A randomized, double-blind, multicenter trial comparing Fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis. *Cutis.* 2001 Apr;67(4 Suppl):2-9.
5. Jegasothy B, Jacobson C, Levine N, Millikan L, Olsen E, Pinnell S et al. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. *Int J Dermatol.* 1985 Sept;24(7):461-5.
6. Jorizzo J, Levy M, Lucky A, Shavin J, Golderg G, Dunlap F et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. *J Am Acad Dermatol.* 1995 Jul;33(1):74-7.
7. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus Clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. *Clin Ther.* 1995 May-Jun;17(3):390-401.
8. Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children – two comparative studies with Fluticasone propionate (0.05%) cream. *J Dermatolog Treat.* 2003 Sep;14(3):141-8.
9. Lebwohl M. et al. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. *Int J Dermatol*. 1999 Aug;38(8):604-6.

10. Lexicomp Online [accessed 2012 April] http://www.lexi.com.
11. Pharmacist's Letter [accessed 2014 Feb] http://pharmacistsletter.therapeuticresearch.com.
12. RxList [accessed 2012 April] http://www.rxlist.com/.

Immunomodulators

1. Clinical Pharmacology [Accessed 2015 March]. Available from: URL: http://www.clinicalpharmacology-ip.com/Default.aspx.
2. Elidel [package insert]. Novartis Pharmaceuticals Corp. East Hanover, NJ; 2010.
3. Protopic [package insert]. Astellas Pharmaceuticals. Deerfield, IL: 2011.
4. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (http://www.fda.gov/cder/ob/default.htm), accessed September 2009.
5. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. *J Am Acad Dermatol*. 2004; 51(4): 515-25.
6. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. *J Am Acad Dermatol.* 2005; 52(5): 810-22.
7. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. *N Engl J Med* 1997; 337(12): 816-21.

Parasitics

1. Clinical Pharmacology. http://www.clinicalpharmacology-ip.com/Default.aspx [Accessed 2015 March].
2. Eurax (crotamiton) prescribing information. Bristol-Myers Squibb Pharmaceuticals. Princeton, NJ: 2003.
3. Natroba (spinosad) prescribing information. Parapro Pharms; Carmel, IN: 2011.
4. Ovide (malathion) prescribing information. Taro Pharmaceuticals. Hawthorne, NY: 2011.
5. Sklice (ivermectin) Lotion, 0.5% prescribing information. Sanofi Pasteur, Inc.; Swiftwater, PA: 2012.
6. Ulesfia [package insert]. Atlanta, GA: Sciele Pharma, Inc.; 2012.
7. Bainbridge CV, Klein GL, Neibart SI, et al. Comparative study of the clinical effectiveness of a pyrethrin-based pediculicide with combing versus a permethrin-based pediculocide with combing. *Clin Pediatr* 1998 Kan;37(1):17-22.
8. Bowerman JG, Gomez MP, Austin RD, et al. Comparative study of permethrin 1% cream rinse and lindane shampoo for the treatment of head lice. *Pediatr Infect Dis J* 1987 Mar;6(3):252-5.

9. Brandenburg K, Deinard AS, DiNapoli J, et al. 1% permethrin cream rinse vs. 1% lindane shampoo in treating pediculosis capitis. *Am J Dis Child* 1986 Sep;140(9):894-6.
10. Chhaiya SB, Patel VJ, Dave JN, et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. *Indian J Dermatol Venereol* Leprol 2012;78(5):605-10.
11. Frankowski BL, Bocchini JA. Academy of Pediatrics Head Lice Guidelines. *Pediatrics* 2010 August;126(2):392-403.
12. Kastrup EK, Ed. Drug Facts and Comparisons (EFacts). Facts & Comparisons. St. Louis. 2009.
13. Meinking TL, Clineschmidt CM, Chen C, et al. An observer-blinded study of 1% permethrin crème rinse with and without adjunctive combing in patients with head lice. *J Pediatr* 2002 Nov;141(5):665-70.
14. Meinking TL, Vicaria M, Eyerdam DH, et al. A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Crème Rinse (1% permethrin) use as labeled, for the treatment of head lice. *Pediatr Dermatol* 2007 Jul-Aug;24(4):405-11.
15. Meinking TL, Vicaria M, Eyerdam DH, et al. Efficacy of a reduced application time of Ovide lotion (0.5% malathion) compared to Nix crème rinse (1% permethrin) for the treatment of head lice. *Pediatr Dermatol* 2004 Nov-Dec;21(6):670-4.
16. Pariser DM, Meinking TL, Bell M, et al. Topical 0.5% ivermectin lotion for treatment of head lice. *N Engl J Med* 2012;367(18):1687-93.
17. Roberts RJ, Casey D, Morgan DA, et al. Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomized controlled trial. *Lancet* 2000 Aug;356(9229):540-4.
18. Schultz MW, Gomez M, Hansen RC, et al. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. *Arch Dermatol* 1990 Feb;126(2):167-70.
19. Stough D, Shellabarger S, Quiring J, et al. Efficacy and safety of spinosad and permethrin crème rinses for pediculosis capitis. *Pediatrics* 2009 Sep;124(3):389-95.
20. Taplin D, Meinking TL, Chen JA, et al. Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. *Pediatr Dermatol* 1990 Mar;7(1):67-73.